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Inflammatory diseases cause considerable morbidity throughout the world. Examples 
of inflammatory diseases include rheumatoid arthritis, Crohn’s disease, 
atherosclerosis and asthma. Current treatments options are insufficient, and novel 
treatment options must be explored. Immunomodulatory proteins observed in nature 
could be repurposed as biotherapeutics, as a form of biomimicry. 
Large double-strand DNA viruses encode a number of virulence proteins which are 
capable of dampening host immune response. Granulocyte-macrophage colony-
stimulating factor (GM-CSF) and Interleukin-2 (IL-2) inhibition factor (GIF) is one 
such protein encoded by orf virus. Orf virus is a zoonotic virus which infects mostly 
sheep and goats. GIF is able to bind ovine and bovine GM-CSF and IL-2, but not 
human variants despite high sequence homology of both cytokines. The expression 
of virulence proteins including GIF allows orf virus to infect and re-infect individual 
animals and herds repeatedly.  
This work reports on the establishment of an expression and purification protocol for 
the GIF protein, an examination of the structural and binding behaviour for GIF, as 
well as the exploration of a potential mechanism for GIF interacting with and 
inhibiting human GM-CSF. 
Work consisted of establishing an expression and purification protocol of GIF in 
enough quantity for downstream experiments. Expression trials optimised the 
amount of DNA used in HEK 293-6E cell transfection, best day of harvest and the 
addition of supplements to the expression mixture. The purification protocol 
involved a three-step fast-performance liquid chromatography purification with an 
additional dialysis step to remove heat-shock protein 70 (HSP70) bound to GIF.  
Binding and modelling studies of GIF were carried out to help explain its biological 
properties. Structural binding experiments confirmed that GIF is subject to N-linked 
glycosylation which is required for secretion from the cell. Enzyme-linked 
immunosorbent assays (ELISAs) confirmed that GIF did not bind human GM-CSF 
or IL-2, but was able to bind bovine GM-CSF. A cell proliferation assay with GM-
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CSF-dependent TF-1 cells revealed that GIF treatment reduced proliferation of cells 
treated with human GM-CSF compared to the no-GIF control, indicating that GIF 
may be able to have some form of interaction with human GM-CSF. We studied the 
interface of the GIF-ovine GM-CSF complex and observed the differences in 
residues between human and ovine GM-CSF. It was concluded that GIF might be 
able to form a transitory interaction with human GM-CSF, however this interaction is 
likely to be weak due to steric hinderance across the binding interface. 
Further examination of the structural basis and binding behaviour of GIF is 
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1. Introduction  
1.1 Chronic inflammation 
1.1.1 Overview 
Inflammatory disease poses a considerable risk to health and a burden to society. 
While inflammation is pivotal for defending the body against infection and injury, 
prolonged and unnecessary inflammation can cause debilitating morbidity and death. 
Inflammatory disease is an umbrella term for diseases where inflammation causes 
undue bodily harm, the list includes; rheumatoid arthritis (RA), asthma, depression, 
cancer, Alzheimer’s disease and atherosclerosis (Bostanciklioglu, 2019; Deng et al., 
2016; Maydych, 2019; Solak et al., 2016). The realisation that inflammation is 
heavily involved in the pathophysiology of many diseases has led to a paradigm shift 
in the field of medicine. Although inflammation has been recognised as a target for 
treatment, clinicians have limited options for treating patients, and no effective cures 
targeting the underlying the causes of disease have been found (Punchard et al., 
2004). 
1.1.2 Biological mechanisms of inflammation 
Inflammation is the innate and immediate reaction of the human body to injury or 
illness. The process is regulated through many complex signalling cascades resulting 
in specialist white blood cells being drawn to the site of injury. The aim of this 
process is to prevent the proliferation of pathogens and to begin the process of 
healing. The five cardinal signs of inflammation are: pain; heat; redness; swelling 
and loss of function. These symptoms reflect the physiological actions of the innate 
immune system as vasodilation occurs and white blood cells are attracted to the 
location of injury or infection (Punchard et al., 2004). Immune cells are able to 
perpetuate inflammation by signalling to other cells via protein mediators, including 
cytokines and chemokines. New evidence suggests that cells of the innate immune 
system may be able to be primed to combat specific pathogens following epigenetic 
changes after first exposure, indicating that the innate immune system may have 
some specificity (Netea et al., 2015).  
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Inflammation is scalable, as signalling mediators can draw differing levels of 
immune cells to the site of injury to reflect the extent of the threat. In addition, 
inflammation can progress in different directions, recruiting different profiles of 
immune cells that are most suitable to respond to specific stimuli. 
Chronic inflammation is a state of disease where inflammation is perpetuated in a 
way which is counterintuitive to improving the patient’s condition. Chronic 
inflammation is the cause of many diseases with pathology involving consistent and 
harmful inflammation at a certain site in the body. This pathology is often described 
in layperson’s terms as “the body attacking itself”. This description is not accurate as 
the body is inadvertently perpetuating proinflammatory cascades, causing tissue 
damage and subsequent disease.  
1.1.3 Current treatment regimens are insufficient 
1.1.3.1 Overview 
Inflammatory diseases present a challenge to clinicians because there is no effective 
cure available. As inflammatory disease includes a myriad of diseases, each with 
unique pathophysiology, there is no single drug regimen used for every case. 
Steroids and non-steroidal anti-inflammatory drugs (NSAIDs) are used effectively to 
treat acute inflammation but are usually not appropriate for long-term use due to the 
increased risk of adverse effects. Different classes of drugs are used to treat chronic 
inflammatory diseases, for example disease-modifying antirheumatic drugs 
(DMARDs) and tumour necrosis factor (TNF) inhibitors, which are often used to 
treat rheumatoid arthritis (Rachapalli et al., 2009; Scott and Kingsley, 2006). 
1.1.3.2 Non-steroidal anti-inflammatory drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) can be classified as anti-
inflammatory, antipyretic and analgesic. Their mechanism of action is through the 
inhibition of prostaglandin synthesis by blocking cyclooxygenase enzymes (Peesa et 
al., 2016). While NSAIDs can reduce pain and inflammation in patients with 
inflammatory disease, they fail to target underlying causes of the disease and carry a 
diverse profile of side and adverse effects when used long-term. Side effects range 
from mild nausea to gastric bleeding and ulcer formation. More serious adverse 
effects exhibited by NSAIDs include renal and cardiovascular failure (Harirforoosh 
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et al., 2013), causing some researchers to call for safer formulations (McCarberg and 
Gibofsky, 2012). 
1.1.3.3 Corticosteroids 
Corticosteroids can effectively reduce inflammation and are the most commonly 
prescribed drug for a range of acute inflammatory diseases (Cheng et al., 2014). 
Corticosteroids work by reducing gene suppression of pro-inflammatory factors by 
binding glucocorticoid receptors and also epigenetically by activating histone 
deacetylase 2 (HDAC2) (Barnes, 2006). Corticosteroids cannot be used systemically 
for more than four to five months, as the risk of developing hypercortisolism 
(Cushing’s syndrome) becomes more likely (Nieman, 2015). Furthermore, 
glucocorticoid resistance can affect up to 30% of patients taking it for rheumatoid 
arthritis (Barnes and Adcock, 2009). Cushing’s syndrome is difficult to identify and 
treat; it involves abnormal fat distribution, hypertension and a ‘moon face’, amongst 
other symptoms. The risk of adverse effects in long-term treatment largely excludes 
corticosteroids from treatment regimens for chronic inflammation. 
1.1.3.4 Disease-modifying antirheumatic drugs 
Disease-modifying antirheumatic drugs (DMARDs) are defined as being able to slow 
the progression of rheumatic disease. Originally developed for the treatment of 
rheumatoid arthritis, the use of DMARDs has been extended to other forms of 
chronic inflammation. As the definition suggests, these drugs are unable to cure the 
disease; however, they have a more specific effect than NSAIDs or corticosteroids 
and can slow disease progression. A common DMARD is methotrexate, a drug 
traditionally used in chemotherapy and as an abortifacient. Methotrexate has the net 
effect of reducing leukocyte accumulation, alleviating the progression of 
inflammation (Cronstein et al., 1993). The ability to increase cellular adenosine 
levels is currently the most widely accepted hypothesis explaining the anti-
inflammatory effects of methotrexate (Friedman and Cronstein, 2019). Methotrexate 
has been proven to provide statistically significant improvements to rheumatoid 
arthritis, as well as increasing the time for undifferentiated arthritis to progress to 
rheumatoid arthritis (van Dongen et al., 2007; Weinblatt et al., 1985). Methotrexate 
treatment has also led to a significant increase in adverse effects and subsequently a 
discontinuation of treatment. A retrospective review found that 34% of patients being 
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treated with methotrexate for rheumatoid arthritis withdrew from treatment due to 
adverse effects, largely due to gastrointestinal issues (Nikiphorou et al., 2014). 
1.1.3.5 Tumour necrosis factor inhibitors 
Tumour necrosis factor (TNF) is a proinflammatory cytokine which has been 
implicated in the pathogenesis of many diseases, including: arthritis; inflammatory 
bowel disease (IBD) and depression (Bradley, 2008; Huang et al., 2019). TNF has 
long been known to be elevated in the synovial fluid of affected joints in patients 
with RA (Di Giovine et al., 1988; Saxne et al., 1988), making TNF a target for 
therapeutic treatment. TNF inhibitors are used for the treatment of inflammation, 
particularly in case of rheumatoid arthritis (Ma and Xu, 2013). TNF inhibitors bind 
and inhibit free TNF in the extracellular membrane and membrane-bound TNF, 
thereby preventing signal transduction resulting in inflammation (Lis et al., 2014). 
While different TNF inhibitors have considerably varied response rates, co-treatment 
with methotrexate has been reported to result in better treatment outcomes (Aaltonen 
et al., 2017). Most TNF inhibitors are monoclonal antibodies (mAbs), which have 
more serious side and adverse effects than non-biological treatments, including a 
significantly increased risk of death for female patients compared to placebo in 
treatment for rheumatoid arthritis (Jacobsson et al., 2007). Studies have consistently 
reported that patients treated with TNF inhibitors are significantly more likely to 
suffer adverse effects, including serious infections (Bradley, 2008). The reduced 
immune functionality induced by TNF inhibitors excludes the treatment of patients 
with chronic infectious diseases, including cancer, tuberculosis; HIV and Hepatitis B 
(Ma and Xu, 2013).  
1.1.4 Summary 
There is currently a requirement for more effective and specific treatment options for 
inflammatory disease. Current standard-of-care treatments including NSAIDs and 
corticosteroids fail to target underlying causes of the disease, while more specific 
treatments like TNF inhibitors can only be used for specific diseases and carry a 
significantly increased risk of adverse effects. There is a need for the development of 
novel therapies which target underlying causes of the disease with a reduced risk of 
adverse effects.  
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1.2 Recombinant protein therapy  
1.2.1 Overview  
Recombinant protein therapy is an emerging and rapidly growing field, with 
biotherapeutic drugs being approved at a greater rate than ever before (Lagassé et al., 
2017). Biotherapeutics now make up over 20% of global pharmaceutical sales, with 
mAbs making the top ten of these drugs (Elvin et al., 2013). Recombinant protein 
drugs have the potential to efficaciously target specific factors to treat disease with 
minimal side-effects. Recombinant protein therapy is the use of proteins optimised 
through recombinant DNA technology to treat disease. Recombinant protein therapy 
comes under the classification of ‘biotherapy’, a class of treatments produced by a 
biological source (Lagassé et al., 2017). 
An example of recombinant protein therapy is insulin for the treatment of diabetes. 
Prior to the introduction of recombinant protein technology, insulin was harvested 
from the pancreases of pigs and cattle. This practice carried the risk of allergic 
reactions, presenting a risk to already vulnerable patients. Insulin is now produced in 
Escherichia coli or Saccharomyces cerevisiae cells using constructs based upon 
human insulin (Ladisch and Kohlmann, 1992).  
Monoclonal antibodies represented the largest proportion of protein drugs approved 
by the FDA, comprising 48% of 62 approved proteins between 2011 and 2016. 
Coagulation factors and enzyme replacement therapy drugs made up the next largest 
classes (Lagassé et al., 2017). Recombinant protein therapy has advantages over 
traditional therapy as the proteins can be engineered to provide superior specificity 
and efficacy. mAbs have proven particularly efficacious in oncology; drugs such as 
Herceptin target specific cancer genotypes have resulted in considerably improved 
patient outcomes (Pento, 2017).  
1.2.2 Recombinant proteins allow specific and efficacious therapy 
The development of a protein drug differs greatly to the development of a chemical 
drug. While other drugs can be synthesised in an optimised process, a protein must 
first be expressed in a living cell expression system and then purified to a standard 
that is acceptable for use in humans. Proteins are inherently larger and more dynamic 
than synthetic drugs. Secondary, tertiary and quaternary structure of the protein must 
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also be stable enough to be efficacious and to exclude unwanted interactions. 
Proteins can also have substantial post-translational modifications, which must be 
produced and maintained consistently to meet standards and still have the desired 
therapeutic effect. The benefit of differential protein structure is that drugs can be 
modified to have properties more suitable to individual diseases, which is of 
increasing interest in the field of biotherapeutic drug development (Mathaes and 
Mahler, 2018). 
 
1.2.3 Protein drug development 
The process for developing biological therapies can differ greatly to the development 
of non-biological drugs. Due to the specificity of protein drugs, the clinical trial 
phase is more complicated as the behaviour of the protein drug differs considerably 
between species. Under the US jurisdiction, applicants must nominate test animals 
whose immune systems match our own. For a protein immunotherapeutic which 
displays vastly different behaviour between species, chimpanzees may need to be 
used for testing. An advantage for the developer is a longer patent, 12 years 
compared to five for new non-biologics. 
Concerns have been raised about the batch consistency of protein drugs, as the 
production of proteins in biological sources involves many parameters, which could 
lead to changes in the final product. Studies have demonstrated that with suitable 
techniques, acceptable batch consistency can be achieved in HEK 293 cells (Ding et 
al., 2017).  
The Food and Drug Administration of the United States and the European Medicines 
Agency have both implemented thorough quality control checks to ensure the quality 
and consistency of both live biotherapeutics and biologically produced protein drugs. 
While the process of producing protein drugs is more complicated, the rewards can 
be measured by therapeutic outcome. Where synthetic drugs have failed, protein 
drugs may be able to modulate specific targets to provide effective therapy for 
chronic inflammation.  
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1.2.4 Protein engineering 
Protein engineering is the process of modifying protein structure to change the 
biochemical properties of a protein. The biochemical properties altered include 
specificity, optimal temperature, optimal pH, efficacy and affinity. 
There are two main methods for protein engineering; rational design and directed 
evolution. Rational design often involves examining the structure of a protein and 
modifying it to optimise its behavioural characteristics. This has led to the design of 
a novel protein fold, which has never been observed in nature (Kuhlman et al., 
2003). The novel protein is called “Top7”, is comprised of 97 amino acids and 
consists of an α/β topology.  
Rational design is often achieved through site-directed mutagenesis, a process where 
the DNA encoding the protein of interest is mutated to result in specific amino acid 
mutations in the primary protein sequence. A drawback of rational design is that the 
tertiary structure of a protein and the effects any changes may have on protein 
function are difficult to predict. 
Directed evolution often involves developing mutant proteins and testing 
characteristics. Mutagenesis can be performed by using a low-fidelity DNA 
polymerase to amplify a protein-encoding gene of interest by polymerase chain 
reaction (PCR). This is usually done in a high-throughput setting, as many mutants 
will exhibit no change in structure or function. Directed evolution is also called 
irrational design, describing the inherently random basis of developing mutants. 
A protein does not need to be well understood for engineering by directed evolution. 
A library of mutants can be made with the effects of each mutant noted, allowing the 
identification of crucial residues and post-translational modifications (Packer and 
Liu, 2015).  
The two methods can be combined in a process called semi-rational engineering. 
Both strategies are useful for developing proteins in a biotherapeutic setting and can 
vastly improve protein function. 
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1.3 Viruses encode immunomodulatory proteins as virulence 
factors 
1.3.1 Overview 
An immunomodulatory protein is any protein capable of altering immune system 
activity. Immunomodulatory proteins with the purpose of modulating the activity of 
another organisms’ immune function are utilised by organisms such as viruses, 
bacteria and parasites to evade immune detection, allowing proliferation. The nature 
of these proteins varies considerably based upon the organism that encodes them. 
The majority of immunomodulatory proteins encoded by viruses are within the 
families Herpesviridae and Poxviridae (McFadden and Murphy, 2000). 
Table 1.1 Viral immunomodulatory proteins of medical interest 
Protein Source species Protein effect Reference 
Interleukin-10 
orthologue 
Orf virus Reduces recruitment of 
monocytes, dendritic 
cells and mast cells to 
inflamed skin. 
Accelerates wound 
healing in mice, 
accelerates resolution of 
exuberant granulation 
tissue on horses (when 
cotreated with orf 
VEGF orthologue) 
(Bennett et al., 
2016; Wise et al., 




Differs to hIL-10. 
Stimulates monocytes 
into pro-inflammatory 













Interacts with only 
VEGFR-2 and 
neuropilin-1, 
endogenous VEGF also 
binds VEGFR-1 and 
VEGFR-3.  
(Lyttle et al., 




GIF Orf virus Binds and inhibits ovine 
and bovine GM-CSF 
and IL-2 








Sequesters viral dsRNA 
to prevent detection by 
host immune system 
(McInnes et al., 
1998) 






Stimulates T-helper cell 
type 2 immune 
response. The type 1 
immune response builds 
adaptive immunity and 
is generally more 






1.3.2 Orf virus 
Orf virus (ORFV) is a Parapoxvirus that is the causative agent of orf, a zoonotic 
disease which primarily affects sheep, goats and cattle. In the farming community 
ORFV is commonly referred to as ‘scabby mouth’ or ‘thistle disease’, which aptly 
describe the appearance of the disease and the mode of transmission, respectively. 
Orf causes blisters and pustules on the skin of infected animals, frequently on the 
mouth and teats, which can prevent young animals from suckling. ORFV does not 
spread systemically; it enters the host through damaged skin and replicates within 
regenerating epidermal keratinocytes (Fleming and Mercer, 2007; McKeever et al., 
1988). ORFV is remarkable in that it can reinfect the same animal repeatedly, in 
spite of a significant host immune response (Haig and McInnes, 2002). The disease is 
described as self-limiting and usually resolves within six to eight weeks, with 
subsequent infections resolving in incrementally shorter time periods (Haig and 
Mercer, 1998).  
ORFV can infect the skin of humans who work with animals or in meat processing; 
however, treatment is usually not required. Immunocompromised human patients 
have been reported to have larger than normal lesions, which, in one case, resulted in 
the amputation of a finger (Groves et al., 1991).  
The observed immune evasion by ORFV is likely due to the presence of several 
genes encoding immunomodulatory proteins, each targeting different host immune 
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capabilities with high specificity (Lalani and McFadden, 1997). These proteins 
include: a chemokine-binding protein (CKBP); an IL-10 orthologue; a vascular 
endothelial growth factor (VEGF) orthologue; a granulocyte-macrophage colony 
stimulating factor and IL-2 inhibition factor (GIF) and an interferon-resistance 
protein (Deane et al., 2000; Fleming et al., 1997; Haig et al., 1998; Lyttle et al., 
1994; McInnes et al., 1998; Seet et al., 2003). It is likely that these proteins are 
virulence factors, not essential for viral replication but necessary for an effective 
ORFV infection. This has been proven for the VEGF orthologue, IL-10 orthologue 
and CKBP in separate experiments, as the extent of infection was significantly 
compromised when either a VEGF, IL-10 or CKBP knockout strain of ORFV was 
used to infect sheep (Fleming et al., 2007; Fleming et al., 2017; Savory et al., 2000). 
Genetic analysis supports this hypothesis as the genes encoding immunomodulatory 
proteins are located on the periphery of the ORFV genome. This is typical of 
virulence factors, as essential genes tend to be conserved in the central region of the 
genome (Fleming et al., 1993). 
While immunomodulatory proteins encoded by ORFV display remarkable similarity 
to endogenous variants, most have undergone considerable adaptation. For example; 
the IL-10 homologue encoded by ORFV retains only immunosuppressant effects, 
while mammalian IL-10 has some pro-inflammatory roles. No endogenous receptors 
can bind both IL-2 and GM-CSF like GIF (Deane et al., 2000; Haig et al., 2002).  
1.3.3 Immunomodulatory proteins encoded by other organisms  
Immunomodulatory proteins are utilised by a range of fungi, bacteria and parasites. 
Like immunomodulatory proteins from large dsDNA viruses, these proteins largely 
appear to have the primary purpose of dampening the host immune response. 
Immunomodulatory proteins from large dsDNA viruses appear to originate from host 
genomes by horizontal gene transfer (Chen et al., 2016). Many of these viral 
immunomodulatory proteins have already proven to be effective in immune system 
subversion in humans and higher mammals (Table 1.1). It can be argued that viral 
immunomodulatory proteins are more suitable candidates to be repurposed as 





The GIF protein is one of the virulence proteins encoded by ORFV. GIF forms an 
obligate dimer which binds and inhibits two of either GM-CSF or IL-2. By targeting 
GM-CSF and IL-2, GIF is simultaneously targeting two separate immune pathways. 
GIF can bind ovine and bovine GM-CSF and IL-2, but not human or murine variants 
(Deane et al., 2000). GIF binds both GM-CSF and IL-2 with high affinity, and recent 
biolayer interferometry experiments have reported that GIF binds ovine GM-CSF 
(oGM-CSF) and ovine IL-2 (oIL-2) with Kd values of 27 nM and 0.47 nM, 
respectively (Felix et al., 2016). Interestingly, the profile of binding to each cytokine 
differs; GIF binds oGM-CSF with slow association and very slow dissociation, while 
GIF binds oIL-2 with fast association and moderately slow dissociation kinetics 
(Felix et al., 2016). 
1.3.5 Effects of GIF on host immunity 
GM-CSF was originally recognised as a haemopoietic growth factor due to its ability 
to stimulate differentiation of cells to granulocytes and macrophages; however, it is 
now understood to be a central mediator of tissue inflammation (Becher et al., 2016). 
GM-CSF is primarily involved in the stimulation of monocytes and granulocytes for 
the initial immune response; however, it is also capable of stimulating dendritic cells 
for priming the adaptive immune response. Monocytes circulate in the bloodstream 
and can be recruited to tissue before developing into macrophages and dendritic cells 
(Shi and Pamer, 2011). Macrophages are essential for the initial immune response as 
they phagocytose pathogens and foreign material; they can also prime the adaptive 
immune system as they can be stimulated to act as antigen-presenting cells (Unanue, 
1984). Dendritic cells are antigen-presenting cells, which process and present 
antigens to T-cells. Granulocytes stimulated by GM-CSF include neutrophils, 
basophils and eosinophils. The described immune interactions of GM-CSF firmly 
class it as a pro-inflammatory agent, and indeed it has been detected in high 
concentrations in chronically inflamed tissue. GM-CSF has been identified as a 
target for therapy for rheumatic disease, and monoclonal antibodies targeting GM-
CSF and the GM-CSF receptor are in development (Becher et al., 2016; Behrens et 
al., 2015; Hamilton, 2015). 
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IL-2 is primarily involved in the stimulation of regulatory T-cells, however it is also 
able to activate cytotoxic lymphocytes (Boyman and Sprent, 2012). The IL-2 
receptor (IL-2R) has three subunits, IL-2α (CD25), IL-2Rβ (CD122) and γc (CD132). 
All three subunits are needed for full signal transduction (Dembic, 2015), which is 
referred to as the trimeric receptor. Signal transduction through the cascade can still 
occur with IL-2Rα and IL-2Rβ; the dimeric receptor, albeit with 10-100-fold lower 
transduction than the trimeric receptor.  
IL-2 binds receptors in a stepwise manner, first binding with IL-2Rα, then IL-2Rβ 
and finally γC. The γC is shared with other cytokines for signal transduction. 
Regulation through receptor affinity is an important regulatory step as different cell 
types maintain differing ratios of low to high affinity complexes (Arenas-Ramirez et 
al., 2015). 
1.3.6 Structure of the GIF protein 
The GIF protein forms an obligate dimer and binds two of either GM-CSF or IL-2, 
an effective stoichiometry of 1:1. The GIF protein resembles neither of its target 
cytokine receptors, instead rendering a conformation with ‘decoy’ hotspots to bind 





Figure 1.1 Structure of the GIF protein. Modified from Felix et al. 2016. Image is a combination of 
a negative stain electron microscope (EM) image of GIF in complex with oIL-2; and the X-ray crystal 
structure of GIF in complex with oGM-CSF. IL-2 and GIF monomers annotated. Helices of IL-2 are 
labelled. Distance shown in angstroms. The R188 residue which is involved in GIF:IL-2 binding 
affinity is labelled and displayed in red. Black outline of oGM-CSF n complex with GIF traced into 
model. Image used in accordance with a Creative Commons Attribution 4.0 license. 
1.3.7 Poxvirus immune evasion domain 
The GIF protein appears to share a similar structural scaffold, the Poxvirus Immune 
Evasion (PIE) domain with other immunomodulatory proteins from Poxviruses 
(Felix et al., 2016). The term was coined by Nelson et al., describing a β-sandwich 
fold retained by unrelated immunomodulatory proteins despite low primary sequence 
homology (Nelson et al., 2015). Proteins with PIE domain structure typically bind 
chemokines or cytokines, have three to four disulfide bonds and have endogenous 
secretion peptides for cell secretion. While these characteristics are retained, the 
exact positioning of loops, electrostatic pattern and binding specificities vary by 
protein to allow for target specificity (Nelson et al., 2015).  
1.3.8 GIF is subject to Asparagine-linked glycosylation  
Glycosylation is an important form of post-translational modification with 
considerable implications for pharmacokinetics of recombinant protein drugs. 
Asparagine-linked (Asn-linked) glycosylation typically delays elimination time of 
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protein drugs, and adding N-linked glycosylation sites can subsequently increase 
biological activity (Kontermann, 2011).   
The GIF protein is subject to heavy N-linked glycosylation in the host cell, 
accounting for around 25% of the observed mature protein weight. Residues Asn 49, 
Asn 55 and Asn 82 are subject to N-linked glycosylation; in the secondary structure, 
these residues and corresponding glycan units sit on the opposite side of the of the 
GIF protein from the GM-CSF binding domain (Felix et al., 2016). The 
glycosylation is required for GIF secretion from the cell (McInnes et al., 2005).  
McInnes et al. (2005) also reported that the glycosylation of GIF was required for 
binding activity with oGM-CSF and oIL-2. Removing N-linked glycosylation from 
GIF with peptide-N-glycosidase F (PNGase F) resulted in the inability of GIF to bind 
either cytokine when binding was measured by ELISA.  
O-linked glycosylation most often occurs on specific serine and threonine residues; 
however, is difficult to predict, because a simple consensus sequence does not exist. 
Prediction using NetOGlyc 4.0 software did not predict any O-linked glycosylation 
sites, nor have any been reported (Felix et al., 2016; McInnes et al., 2005; Steentoft 
et al., 2013).  
1.3.9 GIF contains a WSXWS- like motif 
The WSXWS motif is conserved in the type 1 cytokine receptor family. The motif is 
required for the transport of protein from the endoplasmic reticulum to the cell 
surface (Hilton et al., 1996).  GIF has little in common with cytokine receptors; 
however, it has retained a WSXWS-like motif; WDPWV. Mutating the asparagine 
and the second tryptophan in the motif prevented secretion of the GIF protein and 
prevented binding activity when quantified by ELISA (McInnes et al., 2005). The 
WSXWS motif in cytokine receptors is involved in secretion and cell surface 
expression, however ala-substitutions in the WDPWV motif in GIF still resulted in 
partial secretion (McInnes et al., 2005). 
1.3.10 GIF encoded by other Parapoxviruses 
Other species within the genus Parapoxvirus are known to encode functioning GIF 
proteins. Bovine-specific pseudopox virus (PCPV) and bovine papular stomatitis 
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virus (BPSV) both also encode a GIF protein homolog, with 88% and 37% primary 
sequence identity to ORFV-encoded GIF, respectively. PCPV-encoded GIF has been 
reported to have similar binding kinetics when binding ovine and bovine GM-CSF 
and IL-2, while BPSV-encoded GIF shows no binding (Deane et al., 2009). A PCPV 
variant obtained from a camel has been reported to have a frameshift mutation, 
resulting in a truncated protein missing a crucial cysteine residue (Nagarajan et al., 
2015).   
1.3.11 Scope for new insight  
Collective understanding of the GIF protein has grown considerably since its first 
description in 2000, but there is still much to uncover. The binding mechanism of 
GIF with oGM-CSF has been determined; however, the binding mechanism of GIF 
with bovine GM-CSF and IL-2 variants remains unknown.  
It remains unclear how GIF can bind ovine and bovine GM-CSF and IL-2 but not 
human or murine variants, despite high structural homology. Studying the binding 
behaviour of GIF with each cytokine variant and comparing this to specific residue 
changes along the binding interface may reveal important hotspots. This information 




1.4 Research aims 
The ultimate goal is to use the GIF protein as a template for novel drug design. To 
achieve this goal, there are a number of steps that can be taken to help fill gaps in our 
understanding of GIF. These steps comprise the aims of this thesis. 
Aim 1. Establish a pipeline for efficient GIF production  
The establishment of a standard GIF expression and purification protocol for 
downstream analysis will assist in further studies involving GIF. This aim involved 
design of a construct optimised for GIF expression, expression trials to optimise the 
day of harvest post-transfection, amount of DNA used in transfection and the 
addition of supplements to HEK 293-6E cells to increase cellular expression.  
Aim 2. Establish binding profile of GIF with target cytokines 
The GIF protein binds ovine and bovine cytokines, but not human variants despite 
high primary structure identity. These interactions were explored using ELISAs and 
cell proliferation assays as a basis for in silico work to help explain the binding 
behaviour of GIF. 
Aim 3. Use in silico techniques to explain observed binding behaviour 
The structural basis behind the binding profile of GIF is currently unexplained. To 
explore this information from the literature, binding experiments and sequence 
analysis was used to explain the binding specificity of GIF. This involved primary 
sequence analysis of cytokine variants and comparing individual residue profiles and 




2 Materials and methods 
This chapter describes the materials and methods used throughout this project. 
2.1 Materials and equipment 
2.1.1 Chemicals 
Unless otherwise stated: 
- All chemicals and reagents were analytical grade 
- All solutions, buffers and media preparations were made up with water 
- All solutions and buffers were filtered through 0.45 µm filters 
- All media was sterilised by autoclaving for 20 minutes 
- All solutions for DNA manipulation were filtered through 0.2 µm filters 
2.1.2 General lab equipment  
- Milli-Q™ Academic A10™ (Merck) 
- DNA Engine® Thermocycler (Bio-Rad) 
- 5810R centrifuge (Eppendorf) 
- A-4-81 rotor (Eppendorf) 
- 5415R centrifuge (Eppendorf) 
- FA-45-24-11 rotor (Eppendorf) 
- PTC-0200 DNA Engine® Thermocycler (Bio-rad) 
- Gel Doc™ XR+ (Bio-Rad) 
- Bucket autoclave (Mercer) 
- Powerpac Basic Supply (Bio-Rad) 
- Multi-Blok® 2093 Block Heater (Lab-Line) 
- Laboratory incubator (Axyos)  
- Innova® 40 platform shaker (New Brunswick Scientific) 
- Innova® 2300 platform shaker (New Brunswick Scientific) 
- Sonifier® 350 Cell disruptor (Branson) 
- Sub Aqua 12 Waterbath (Grant Instruments) 
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2.1.3 Subcloning and transformation 
2.1.3.1 DNA plasmid isolation 
For a small-scale isolation, the Purelink™ HiPure Plasmid Miniprep kit (Invitrogen) 
was used. For large-scale isolation, the Plasmid Mega kit (Qiagen) was used. 
Purelink™ HiPure Plasmid Miniprep kit (Invitrogen) 
Equipment 
- 2.5 mL Purelink™ anion-exchange columns 
Buffers 
- “R3” resuspension buffer (Invitrogen): 50 mM Tris-HCl, pH 8.0, 10 mM 
EDTA, 20 mg/mL RNase A 
- “EQ1” Equilibration buffer: 0.1 M Sodium acetate, pH 5.0, 0.6 M NaCl, 0.15 
% (v/v) Triton® X-100  
- “L7” Lysis buffer (Invitrogen): 0.2 M NaOH, 1% (w/v) SDS 
- “N3” Precipitation buffer (Invitrogen): 3.1 M potassium acetate, pH 5.5 
- “W8” Wash buffer: 0.1 M sodium acetate, pH 5.0, 825 mM NaCl 
- “E4” Elution buffer: 100 mM Tris-HCl, pH 8.5, 1.25 M NaCl 
Plasmid Mega kit (Qiagen) 
Equipment 
- 35 mL anion-exchange DNA-binding columns (Qiagen) 
Buffers 
- “P1” Resuspension buffer: 50 mM Tris-HCl, 10 mM EDTA, 100 ug/mL 
RNase A, pH 8.00 
- “P2” Lysis buffer: 200 mM NaOH, 1% (w/v) SDS 
- “P3” Neutralisation buffer: 3.0 M CH3CO2K, pH 5.5, adjusted with glacial 
acetic acid 
- “QBT” Equilibration buffer: 750 mM NaCl, 50 mM MOPS, 15% (v/v) AR 
Isopropanol, 0.15% Triton-X100, pH 7.0 
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- “QC” Wash buffer: 1.0 M NaCl, 50 mM MOPS, 15% (v/v) AR isopropanol, 
pH 7.00 
- “QF” Elution buffer: 1.25 M NaCl, 50 mM Tris-HCl, 15% (v/v) AR 
isopropanol, pH 8.5 
- Tris-EDTA (TE) Buffer: 10 mM Tris-HCl, 1 mM ethylenediaminetetraacetic 
acid (EDTA), pH 8.0 
2.1.3.2 DNA restriction endonuclease digests 
- HindIII restriction enzyme (Roche) 
- EcoR1 restriction enzyme (Roche) 
- 10x buffer B (Sigma): 100 mM Tris-HCl, pH 8.0, 50 mM MgCl2, 17.1 mM 
NaCl  
2.1.3.3 DNA dephosphorylation 
- rAPID alkaline phosphatase (Roche) 
- rAPID alkaline phosphatase 10x buffer (Roche) 
2.1.3.4 DNA ligation 
- T4 DNA ligase (Roche) 
- T4 DNA ligase buffer (Roche): 660 mM Tris-HCl, 50 mM MgCl2, 50 mM 
DTT, 10 mM ATP, pH 7.5. 
2.1.3.5 DNA purification 
High Pure PCR Product Purification Kit (Roche) 
Equipment 
- 700 µL Fibre glass DNA-binding columns 
Buffers 
- Binding buffer: 3 M guanidine-thiocyanate, 10 mM Tris HCl, 5% ethanol 
(v/v), pH 6.6 
- Washing buffer: 20 mM NaCl, 2 mM Tris-HCl, pH 7.5. 
2.1.3.6 Primers 
Forward and reverse primers for amplification of GIF construct insert DNA 
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2.1.3.7 Plasmids and constructs 
Plasmid for transient transfection 5 (pTT5) 
pTT5 is used for transient transfection in HEK 293-6E cells. pTT5 encodes 
ampicillin resistance, a multiple-cloning site (MCS), OriP and a Cytomegalovirus 
(CMV) promoter/enhancer. 
Green fluorescent protein pTT5 construct 
A construct with DNA encoding green fluorescent protein (GFP) for use as a positive 
control for cellular expression and a negative control for western blotting using a 
His-antibody. 
“EcoD” 
A segment of the orf virus genome including the gene encoding GIF. EcoD was a 
gift from the Viral Research Unit and was used as template DNA. 
2.1.3.8 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed using a PowerPac™ basic (Bio-Rad) 
- 1% agarose gel: 1% (w/v) agarose in 1x TAE buffer 
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- 50x Tris-Acetate-EDTA buffer: 2 M Tris-HCl, 1 M glacial acetic acid, 50 
mM EDTA, pH 8.5 
- 1x Tris-acetate-EDTA buffer: 50x tris-acetate-EDTA buffer diluted 1 in 50 
with type-1 H2O 
- Ethidium bromide (10 mg/mL) (Fluka) 
- 1 kb plus DNA ladder (Invitrogen) 
- 6x bromophenol blue DNA loading dye: 30% (v/v) glycerol, 0.25% (w/v) 
bromophenol blue 
- 6x Orange G DNA loading dye: 10 mM Tris HCl, 60% (v/v) glycerol, 0.15% 
(w/v) Orange G, 60 mM EDTA 
2.1.3.9 Polymerase chain reaction 
DNA amplification using polymerase chain reaction (PCR) was performed using a 
DNA engine® thermocycler (Bio-Rad). 
- Phusion® high-fidelity DNA polymerase (2 U/µL) (Thermo Fisher 
Scientific)  
- Phusion® 5x high-fidelity buffer (Thermo Fisher Scientific) 
- DMSO (Sigma) 
- PCR DNA nucleotide mix (Sigma) (Formulation is propriety so exact 
concentration is unknown) 
2.1.3.10 DNA isolation from agarose gel 
- Freeze N’ Squeeze™ (Bio-rad) 
- Sterile scalpel (Swann Morton, Sheffield) 
2.1.3.11 Heat-shock competent cells 
Heat-shock competent E. coli DH5α™ (Life Sciences) 
F- endA1 recA1 galE15 galK16 nupG rpsL ΔlacX74 Φ80lacZΔM15 araD139 Δ 
(ara, leu)7697 mcrA Δ (mrr-hsdRMS-mcrBC) Λ-  
2.1.3.12 Media for bacterial growth  




- LB-agar plates: 1% Casein peptone N1 (w/v), 1% NaCl (w/v), 0.5% yeast 
extract, 1.5 % (w/v) agar  
- ZY media: 10% (w/v) Casein peptone N1 (w/v), 5% (w/v) yeast extract, 50 
mM NH4Cl, 25 mM Na2HPO4, 25 mM KH2PO4, 5 mM Na2SO4, 2 mM 
MgCl2, 0.5% (v/v) glycerol, 0.05% (w/v) glucose. 
2.1.4 Expression, purification and protein analysis 
2.1.4.1 HEK 293-6E cell culture 
- HEK 293-6E cells (Durocher, Montreal) 
- 1x Phosphate buffered saline (PBS) 
- Freestyle™ 293 Expression Medium (Gibco) 
- Geneticin (Gibco) 
- Pluronic™ F-68 Non-ionic Surfactant (Gibco) 
- 0.4% Trypan blue stain (Gibco) 
- Lab Culture Type 2 Biological safety cabinet (ESCO) 
- Forma Steri-cycle CO2 incubator (Thermo Fisher Scientific) 
- RC5C centrifuge (Sorvall) 
- Fiberlite ™ F 10S-6x500y rotor (Thermo Fisher Scientific) 
- 0.0025 mm2 Neubauer-improved counting chamber (Marienfield) 
- TS100 Eclipse light microscope (Nikon) 
2.1.4.2 SDS-PAGE gel electrophoresis  
Equipment 
- Mini-PROTEAN® TGX™ precast gels, 4-20% (Bio-Rad)  
- Mini-PROTEAN® 3 Cell Electrophoresis Chamber (Bio-Rad) 
- Powerpac™ Basic Supply (Bio-Rad) 
Buffers and solutions 
- Precision Plus Protein ™ standard (Bio-Rad) 
- Novex ™ Sharp Pre-stained Protein Standard (Thermo Fisher Scientific) 
- Coomassie Brilliant Blue G-250 (Sigma-Aldrich) 
- Staining solution: 0.1% (w/v) Coomassie Brilliant Blue G-250 (Sigma-
Aldrich), 50 % (v/v) methanol, 10% (v/v) acetic acid 
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- De-staining solution: 20% (v/v) methanol, 10% (v/v) acetic acid 
- 10x SDS-PAGE running buffer: 250 mM Tris-HCl, 1.92 M glycine, 1% (w/v) 
SDS, pH 8.3 
- 1x SDS-PAGE running buffer: 10x SDS-PAGE running buffer diluted 1 in 10 
with type-1 H2O 
- 5x SDS-PAGE loading buffer: 164.5 mM Tris-HCl, 65.7% (v/v) glycerol, 
5.25% (w/v) SDS, 0.025% (w/v) bromophenol blue, 12.5 (v/v) β-
mercaptoethanol, pH 6.8 
2.1.4.3 Western blotting 
Equipment 
- Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad) 
- PowerPac™ 300 Electrophoresis Power Supply (Bio-Rad) 
- Extra Thick Blot Filter Paper, pre-cut, 7 x 8.4 cm (Bio-Rad) 
- LAS-3000 Imager (Fujifilm) 
Buffers and reagents  
- Immobilon-P ™ 0.45 µm PVDF transfer membrane (Millipore) 
- Primary antibody: Tetra-His BSA-free antibody (Qiagen) (Cat. # 34670) 
- Secondary antibody: Anti-mouse IgG, HRP-linked antibody (Cell signalling 
technology) (Cat. # 7056S) 
- SuperSignal™ West Pico PLUS Chemiluminescent substrate kit (Thermo 
Fisher Scientific) 
- SuperSignal® West Pico Luminol Enhancer Solution (Thermo Scientific) 
- SuperSignal® West Pico Stable Peroxide Solution (Thermo Scientific)  
- Anode I buffer: 300 mM Tris-HCl, 10% (v/v) methanol, pH 10.4 
- Anode II buffer: 25 mM Tris-HCl, 10% (v/v) methanol, pH 10.4 
- Cathode buffer: 25 mM Tris-HCl, 40 mM Glycine, 10% (v/v) methanol, pH 
9.4 
- PBST washing buffer: 7.2 mM Na2HPO4, 1.47 mM KH2PO4, 2.7 mM 
KH2PO4, 137 mM NaCl, 0.2% (v/v) Tween-20 
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- PBST blocking buffer: 7.2 mM Na2HPO4, 1.47 mM KH2PO4, 2.7 mM 
KH2PO4, 137 mM NaCl, 0.2% (v/v) Tween-20, 0.1% (w/v) Trim milk 
powder (Anchor) 
2.1.4.4 ÄKTA™ Purification system 
Equipment 
- ÄKTA™ purifier 10 (GE) 
- His-trap FF crude 5 mL column (GE) 
- Superdex 75 (GE) 
- Superose 12 10/300 column (GE) 
- MonoQ 4.6/100 PE column (GE) 
Buffers 
- IMAC Binding buffer: 50 mM NaH2PO4/Na2HPO4, 250 mM NaCl, 10 mM 
imidazole, pH 7.3 
- IMAC Elution buffer: 50 mM NaH2PO4/Na2HPO4 pH 7.3, 250 mM NaCl, 
500 mM imidazole, pH 7.3 
- His-trap FF crude 5 mL column (GE) stripping buffer: 20 mM 
NaH2PO4/Na2HPO4, 0.5 NaCl, 50 mM EDTA, pH 7.4 
- SEC Buffer: 50 mM NaH2PO4/Na2HPO4, 250 mM NaCl, pH 7.3 
- IEX Buffer: 50 mM NaH2PO4/Na2HPO4, pH 7.3  
- HSP70 separation buffer:  50 mM Na2PO4, 150 KCl, 4 mM EDTA, pH 6.9 
2.1.4.5 Protein deglycosylation 
In vitro deglycosylation 
Enzymatic deglycosylation kit for N-linked and simple O-linked glycans (Prozyme) 
- PNGase F 
- 5x Incubation buffer: 0.25 M NaH2PO4 pH 7.0 
- Denaturation solution: 2% SDS, 1 M β-mercaptoethanol  
- Detergent solution: 15% Nonyl phenoxypolyethoxylethanol-40 
In vivo prevention of glycosylation  
- DMSO (<99.9%) (Sigma)  
25 
 
- Tunicamycin (Dry powder) (Abcam) 
- Mammalian Protein Extraction Reagent (M-PER™) (Thermo Fisher 
Scientific) 
- Heat Systems Ultrasonic Sonifier Cell Disrupter (Branson) 
2.1.5 TF-1 cell proliferation assay 
- alamarBlue™ (Bio-Rad) 
- Fetal calf serum (FCS) (Gibco) 
- CELLSTAR® T175 flasks (Greiner) 
- 0.0025 mm2 Neubauer-improved counting chamber (Marienfield) 
- Trypan blue stain (Sigma) 
- TS100 Eclipse light microscope (Nikon) 
Passaging growth media: RPMI 1640 (Gibco). 1% sodium pyruvate (Gibco), 1% 
penicillin, streptomycin, kanamycin (Gibco), 5% FCS, 10 ng/mL GM-CSF (R&D 
supply) 
- Assay growth media: Rosewell Park Memorial Institute media (RPMI) 1640 
(Gibco), 1% sodium pyruvate (Gibco), 1% Penicillin, streptomycin, 
kanamycin (Gibco), 2% FCS, 3 ng/mL GM-CSF (R&D supply) 
- Assay media: RPMI 1640 (Gibco), 1% sodium pyruvate (Gibco), 1% PSK 
(Gibco), 2% FCS  
- PBS: 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 
7.4 
- Reagent diluent: PBS, 5% (v/v) Tween-20 
- Wash buffer: PBS, 0.05% (v/v) Tween-20 
- Human GM-CSF growth media: RPMI, 1% sodium pyruvate, 2% FCS, 2 
ng/mL hGM-CSF 
- Bovine GM-CSF growth media: RPMI, 1% sodium pyruvate, 2% FCS, 16 
ng/mL bGM-CSF 
2.1.6 ELISA kits 
Bovine IL-2 DuoSet® ELISA (R&D Technology) 
- Goat anti-bovine IL-2 Capture Antibody  
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- Biotinylated Goat Anti-bovine IL-2 Detection Antibody  
- Recombinant bovine IL-2 Standard  
- Streptavidin Horse Radish Peroxidase conjugate  
Human IL-2 DuoSet ELISA (R&D Technology) 
- Goat anti-human IL-2 capture antibody  
- Biotinylated goat anti-Human IL-2 detection antibody 
- Human IL-2 standard  
- Streptavadin HRP 
Human GM-CSF ELISA set (BD Biosciences) 
- BD OptEIA™ TMB Substrate Reagent Set (BD Biosciences) 
- ELISA secondary antibody – Streptavidin-HRP (BD Biosciences) 
- Human GM-CSF capture antibody 
- Human GM-CSF standard  
Other materials and reagents for ELISA kits 
- 1x PBS  
- PBST wash buffer: 0.05% Tween® 20 in PBS, pH 7.30 
- Normal goat serum 
- 2 N Sulfuric acid 






Table 2.2 List and description of software used throughout this project 
Software name Purpose  Reference or software 
creator 
BioRender Generating scientific 
schematics 
BioRender 
BLASTn Searching for genes by 
sequence, aligning DNA 
sequences 
National Centre for 
Biotechnology 
Information (NCBI) 




Easy sequencing in 
postscript (ESPrit) 
Display primary sequence 
alignments 
(Robert and Gouet, 2014) 
ExPASy translate tool Translation of DNA 
sequence to primary protein 
sequence 
Swiss Institute of 
Bioinformatics 
Geneious Prime 
(Version 2020. 0.3) 




OligoCalc Determine properties of 
primers 
(Kibbe, 2007) 
MASCOT 2.6.00 Protein database used to 
identify proteins from MS 
Matrix Science 
Nanodrop software Analysis of samples 
processed by Nanodrop 
ND-1000 
Nanodrop technologies 
NetNGlyc 1.0  Predict N-linked 
glycosylation 
(Blom et al., 2004) 
NetOGlyc 4.0 Predict O-linked 
glycosylation 
(Steentoft et al., 2013) 
ProtParam Calculation of physical and 
biochemical properties of 
proteins 
Swiss Institute of 
Bioinformatics  




complement sequence of 
DNA 
Dr. Audrius Meskauskas, 
Crealogix AG, 
Switzerland 
SignalP version 4.0 Prediction of secretion 
signal from primary protein 
sequence  
(Petersen et al., 2011) 
Snapgene Viewer 
(Version 4.1.9) 
Visualise DNA sequences GSL Biotech LLC 
SoftMax® Pro 6 Analysing absorbance of 
96-well plates 
Molecular Devices 
UNICORN 5.0  Control software for the 




UniProt Protein database Uniprot Consortium  
 
2.1.8 Manufacturers 
Table 2.3 List of companies and location of headquarters  
Company HQ Location 
Abcam Cambridge, UK 
Anchor Auckland, New Zealand 
Becton Dickinson (BD)  New Jersey, USA 
Bio-Rad California, USA 
Fujifilm Tokyo, Japan 
General Electric  Massachusetts 
Invitrogen California, USA 
Nikon Tokyo, Japan 
Research & Development (R&D) 
Systems 
Minnesota, USA 
Roche Basel, Switzerland 
Sigma Missouri, USA 
Thermo Fisher Scientific Scientific  Massachusetts, USA  





2.2 General protocols 
2.2.1 Antibiotic stock preparation 
Preparation of ampicillin stock solution  
Ampicillin powder was dissolved in type-1 H2O to reach a final concentration of 100 
mg/mL. The solution was filtered through a 0.2 µm regenerated cellulose (RC) filter 
and stored at -20 °C. 
2.2.2 DNA manipulation 
2.2.2.1 Dilution of DNA primers for amplification of the GIF construct 
DNA primers were diluted to stock concentrations of 200 µM in TE buffer and 
stored at -80 °C. Primer stock solutions were diluted to 10 µM in H2O for working 
solutions.  
2.2.2.2 Purification and cleaning of plasmid DNA  
DNA was purified using the High Pure PCR Product Purification Kit (Roche). This 
step occurred to remove impurities after excising DNA from gels, restriction digests 
and dephosphorylation. This kit is also appropriate for purifying larger segments of 
DNA including pTT5. The manufacturer’s instructions were followed, except in the 
final step, where H2O was used to elute DNA instead of TE buffer. 
2.2.2.3 Agarose gel electrophoresis  
Gels were prepared at 0.5-1.5% agarose depending on the size of DNA fragments 
being analysed. The appropriate amount of agarose was dissolved in TAE buffer by 
heating in a 1,000 W microwave for one minute. Ethidium bromide was added to 
reach a final concentration of 0.5 µg/mL. The solution was stirred and poured into a 
gel template. A comb was added to create the wells and the solution was left to set at 
room temperature for 90 minutes. 
DNA samples were mixed with either 6x bromophenol blue (Sigma) loading dye or 
Orange G (Sigma) loading dye. Samples were loaded into an agarose gel for 45 
minutes at 100 volts, or for one hour to separate larger DNA segments, for example 
the pTT5 plasmid. Gels were visualised by UV trans illumination using a Gel Doc™ 
XR+ (Bio-Rad).  
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2.2.2.4 DNA sequencing 
DNA sequencing was performed by Massey Genome Service (MGS) located within 
the Institute of Fundamental Science on the Massey Palmerston North campus. 
Sequencing was performed using an ABI 3730 sequencing machine (Applied 
Biosystems). 
Samples were submitted containing 4 picomolar of appropriate forward or reverse 
primer, 500 ng of appropriate plasmid DNA sample, and topped up to a total volume 
of 20 µL with H2O. pTT5 plasmids were sequenced with primers flanking the MCS. 
The forward and reverse complement were compared to ensure consistency. 
Sequencing results were visualised using SnapGene® Viewer (version 4 .1 .9). 
2.2.2.5 Restriction endonuclease digests 
Reagents were pipetted into a 1.7 mL microcentrifuge tube. Reagent mixes for 
specific experiments are described later in this chapter. The tube was mixed with 
care to ensure all reagents remained in contact at the bottom. The mixture was 
incubated in a water bath for three hours at 37 °C. DNA was subsequently purified 
using the High Pure PCR Product Purification kit (Roche) as described in 2.2.2.2. 
2.2.2.6 Megaprep isolation of construct DNA 
Protocol was based on that of the manufacturer, with several changes. The cell pellet 
from a 450 mL cell culture was obtained by centrifuging cells for 15 minutes at 
8,671 x g in an RC5C centrifuge (Sorvall) using a Fiberlite™ F 10S-6x500y rotor 
(Thermo Fisher Scientific). The pellet was resuspended in 50 mL of “P1” 
resuspension buffer. The cells were lysed by adding 50 mL “P2” lysis buffer and 
mixed by inverting six times. The sample was incubated at room temperature for five 
minutes. The sample was neutralised by adding 50 mL of pre-chilled “P3” 
neutralisation buffer at 4 °C. This was mixed by inverting six times and incubated on 
ice for 30 minutes. The sample was centrifuged at 47,807 x g for 30 minutes in an 
RC5C centrifuge (Sorvall) using an SS-34 rotor (Sorvall). The supernatant was re-
centrifuged at 47,807 x g for 15 minutes.  
A 35 mL Qiagen anion-exchange DNA-binding column was re-equilibrated with 35 
mL of “QBT” equilibration buffer. This was attached to a retort stand. Above the 
column was a column containing Kimwipes, which acted as a filter to ensure the 
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purity of sample applied to the column. The supernatant from the previous 
centrifugation step was filtered through the Kimwipes onto the column. Once the 
sample had been loaded, the DNA was cleaned by pouring 200 mL “QC” washing 
buffer through the column. The DNA was eluted into a 50 mL sterile tube with 35 
mL of “QF” elution buffer. The DNA was precipitated by adding 24.5 mL of room-
temperature isopropanol. The solution was centrifuged at 3,220 x g for 60 minutes in 
a 5810R centrifuge (Eppendorf) using an A-4-81 rotor (Eppendorf) to produce a 
DNA pellet. The supernatant was disposed of, before 10 mL of 70% of ethanol was 
added to wash the DNA. This was centrifuged at 3,220 x g for 60 minutes. The 
supernatant was disposed of and the pellet was left to dry overnight at room 
temperature. 
The pellets were resuspended in 500 µL of TE buffer. The samples were then 
incubated on ice for 30 minutes before a further 500 µL of TE buffer was added to 
each. The samples were diluted to 500 ng/µL, quantified by a Nanodrop-1000. The 
DNA was filtered through a 0.22 µM RC filter in a class-II fume hood before being 
stored at -80 °C. 
2.2.2.7 Assessing DNA quality  
DNA quality was assessed using a Nanodrop-1000 spectrophotometer measuring the 
ratio between A260/A280, with an acceptable ratio being near 1.8. The instrument 
was blanked with 2.5 µL of appropriate buffer, before 2.5 µL of sample was applied 
and analysed. The extinction coefficient at 280 nm of proteins of interest was 
factored into calculations for improved accuracy. 
2.2.2.8 Miniprep isolation of plasmid DNA 
Plasmid DNA was extracted using the Purelink™ HiPure Plasmid Miniprep kit 
(Invitrogen), using the manufacturer’s instructions with some modifications. Water 
was used to elute DNA, not TE buffer. The water was also incubated in the column 
for 10 minutes prior to elution to maximise yield. 
2.2.2.9 Isolation of DNA from agarose gel 
Sample DNA was run on an agarose gel as described in 2.2.2.3. The gel was placed 
on a UV light-emitting plate,  the band of interest was then excised using a razor 
blade. The slice of agarose gel containing the band of interest was transferred to a 
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Freeze N’ Squeeze™ column (Bio-Rad). This was placed in a -20 °C freezer for five 
minutes, before being centrifuged at room temperature at 13,000 x g in a 5145R 
centrifuge (Eppendorf) using a FA-45-24-11 rotor for three minutes. The purified 
DNA was collected in the bottom of the tube while gel debris was trapped in the 
filter. 
2.2.3 Non-adherent HEK 293-6E cell culture 
2.2.3.1 Thawing frozen HEK 293-6E stocks  
Frozen HEK 293-6E cell stocks were stored in a Dewar liquid nitrogen storage unit. 
Frozen stocks were thawed by dipping briefly in a 37 °C water bath. The thawed 
cells were pipetted into a 15 mL conical tube (Greiner) containing 10 mL 
FreeStyle™ 293 Expression medium (Gibco). The tube was mixed gently before 
being centrifuged at 450 x g for five minutes. The supernatant was removed and 
discarded to remove DMSO from the freezing solution, before the pellet was 
resuspended with 1 mL of FreeStyle™ 293 expression medium. This was added to a 
conical flask containing 10 mL of Freestyle™ 293 expression medium with 50 
µg/mL geneticin. The flask was returned to an incubator and split 3 days later. 
2.2.3.2 Counting cells  
To determine the concentration of cells, 10 µL of the cell sample was mixed with 10 
µL of 0.4% Trypan blue stain. Ten µL of the stain and cell mix was loaded onto a 
0.0025 mm2 Neubauer-improved counting chamber (Marienfield) and visualised 
under a TS100 Eclipse light microscope (Nikon) under 40x total magnification. The 
counting chamber had four sets of 16 squares. The total amount of cells were counted 
from each set of 16 squares. The mean average number of cells from the four-square 
sets was calculated.  
2.2.3.3 Passaging cells  
Cells were split to a concentration of 0.25x105 cell per mL in FreeStyle™ 293 
expression medium (Gibco) with 1% Pluronic® F-68 (Gibco). To prevent 
contamination, cells were passaged with 50 µg/mL geneticin (Gibco) from a 70 
mg/mL stock solution. Cells are incubated at 37 °C, 120 RPM and 5% CO2.  
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2.2.3.4 Freezing of HEK 293-6E cells 
Cells were cultured to 5,000,000 cells per mL. Fifty mL of the cell culture was 
centrifuged at 450 x g for five minutes. The supernatant was removed and discarded. 
The pellet was resuspended in 10 mL of freeze media aliquoted into autoclaved 
cryovials. The cells were placed in an isopropanol freezing container and left in a -80 
°C freezer overnight. The isopropanol freezing container reduces the rate of freezing 
to prevent cellular shock. Frozen cell aliquots were later transferred to a Dewar 
liquid nitrogen storage unit. 
2.2.3.5 Transfection of HEK 293-6E cells   
Cells were transfected using specific volumes of DNA, Polyethylenime (PEI) and 
PBS depending on the volume of the cell culture. After preparing the transfection 
mixture, it was vortexed for 30 seconds before being left to incubate at room 
temperature for 15 minutes. The total volume of transfection mix is 10% of the cell 
culture volume. 
2.2.3.6 Harvesting of HEK 293-6E cells 
For large-scale samples, 500 mL centrifuge flasks were filled with cell sample and 
centrifuged in an RC5C centrifuge (Sorvall) using a Fiberlite ™ F 10S-6x500y rotor 
(Thermo Fisher Scientific). Flasks were centrifuged at 6,000 RPM and 4° C for 20 
minutes.  
2.2.4 Protein manipulation 
2.2.4.1 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gels used were mini-
PROTEAN® precast 4-20% TGX™ (Bio-Rad). To prepare samples, appropriate 
volumes of sample and loading buffer were mixed together by creating a vortex.  The 
mixture was placed on a 95° C hot plate for five minutes, before being left to cool on 
ice. The samples were centrifuged for 30 seconds at 500 x g in an 5415R centrifuge 
using an FA-45-24-11 rotor. 
Samples were carefully pipetted into the gel wells. Gels were run in the Mini-
PROTEAN® 3 Cell Electrophoresis chamber (Bio-Rad), powered by the 
PowerPac™ Basic Supply (Bio-Rad). The gel was run for 40 minutes at 200 V. 
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2.2.4.2 Coomassie blue staining 
Coomassie blue was used to stain protein bands on SDS-PAGE gels. Gels were 
stained by submerging in Coomassie blue staining solution and microwaved in a 
1,000 W microwave for one minute. The container containing both gel and stain was 
left on an agitator for 30 minutes. After 20 minutes, the gel was de-stained using de-
stain solution. The stain was poured off and replaced with de-stain solution. This was 
microwaved in a 1,000 W microwave for one minute and placed on an agitator for 30 
minutes. 
2.2.4.3 Western blotting procedure 
A ‘sandwich’ consisting of the gel, polyvinylidene (PVDF) membrane and blotting 
papers soaked in appropriate buffers was assembled. The sandwich was assembled 
from bottom to top in the following order: blotting paper soaked in anode I buffer; 
blotting paper soaked in anode II buffer; PVDF membrane soaked in anode I buffer; 
gel soaked in cathode buffer; and two blotting papers soaked in cathode II buffer. 
Protein semi-dry transfer was performed by running the apparatus at a constant 22 V 
for 30 minutes. Care was taken to remove any air bubbles as well as excess buffer.  
After the transfer, the sandwich was disassembled, and the membrane soaked in 
100% methanol for five minutes on an agitator. The membrane was then washed in 
water and placed in a 50 mL conical tube (Greiner). Twenty mL of phosphate 
buffered saline with tween (PBST) blocking buffer with 10 µL of primary antibodies 
was added to the flask. This was left to incubate overnight on a roller at 4 °C. The 
PBST blocking buffer with primary antibodies was removed from the flask. The 
membrane was washed with 50 mL PBST buffer and incubated on the roller at 4 °C 
for five minutes, three times. The membrane was then soaked in 20 mL PBST 
blocking buffer with 4 µL secondary antibodies and incubated on a roller at room 
temperature for 90 minutes. The PBST blocking buffer with secondary antibodies 
was removed. The membrane was washed with 50 mL PBST buffer and incubated on 
the roller at room temperature for five minutes, three times. 
The membrane was prepared for detection using a Supersignal® West HisProbe™ 
Kit (Thermo Fisher Scientific). One mL of Supersignal® West Pico 
Luminol/Enhancer solution was mixed with 1 mL of Supersignal® West Pico stable 
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peroxide solution and applied to the membrane. The bands were visualised using a 
LAS-3000 imager (Fujifilm). 
2.2.4.4 Heat shock protein 70 removal by dialysis 
GIF was dialysed with EDTA and activated charcoal to separate it from HSP70, the 
rationale is discussed in 6.1.7. Pooled fractions from IEX chromatography were 
transferred to dialysis tubing with a MWCO of 12,000-14,000 (Spectra/Por®). The 
sample in dialysis tubing was placed in 4 L of EDTA dialysis buffer at 4 °C with 
gentle stirring using a magnetic stir bar and stirrer. The sample was left to equilibrate 
overnight in 4 L of HSP70 removal buffer for 16 hours, with the buffer replaced in 
the morning and the sample left to incubate for a further four hours.  
2.2.4.5 Quantification of protein by Bradford assay 
The protein sample was diluted 1 in 30 in room-temperature Coomassie reagent. 
After incubating for 10 minutes at room temperature, the absorbance of standards 
and samples were measured at 595 nm using a NanoDrop™ 2000 spectrophotometer 
(Thermo Fisher Scientific). A standard curve was used to determine the 
concentration of protein samples. This was made using bovine serum albumin 
(BSA), with a serial dilution prepared to concentrations 0.500, 0.250, 0.125, 0.0625, 
0.03125 and 0.01563 mg/mL.  
2.2.4.6 Quantification of protein by NanoDrop™ 1000 
Protein quantity was determined by measuring the sample absorbance at 280 nm 
using a NanoDrop™1000 spectrophotometer (Thermo Fisher Scientific); the molar 
extinction coefficient of GIF was factored in for improved accuracy. 
2.2.4.7 Protein identification by mass spectrometry  
Bands of protein representing unknown protein were subject to mass spectrometry 
(MS) for identification. This involved cutting the band out of the SDS-PAGE gel and 
delivering to the Centre for Protein Research at the University of Otago. Protein was 
subject to tryptic digest before being analysed by liquid chromatography mass 
spectrometry using a nanospray LTQ-Orbitrap XL™ inline coupled to ultimate 3000 
nano-flow ultra-high-performance liquid chromatography.  
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2.2.5 TF-1 cell culture 
TF-1 cells were cultured in CELLSTAR® T175 flasks (Greiner). Cells were 
passaged at least three times before use in experiments. Cells were counted on a 
haemocytometer as previously described in 2.2.3.2. The cells were diluted to 104/mL 
every two days in fresh TF-1 cell culture growth media.  
2.3 Subcloning and transformation 
2.3.1 Prediction of GIF intrinsic secretion signal  
SignalP 4.0 was used to predict the presence of an endogenous secretion signal. The 
FASTA sequence of GIF encoded by orf virus (Strain NZ2) was uploaded to the 
server. The server was instructed to search for mammalian secretion signals as the 
GIF protein is produced and secreted by mammalian cells in situ. 
2.3.2 PCR amplification of GIF DNA insert 
Primers were diluted to a working concentration in H2O as described in 2.2.2.1. PCR 
was set up using reagents as described in Table 2.4, the reaction was run as described 
in Table 2.5. 
Table 2.4 Reaction mix for PCR amplification of GIF DNA 
Reagent Volume (µL) 
5x high fidelity buffer 10 
GIF construct forward primer* 1 
GIF construct reverse primer* 1 
DMSO 1.5 
DNA nucleotides** 1 
Phusion DNA polymerase 0.5 
EcoD template DNA*** 1 
Type-1 water 34 
Total volume 50 
* Primers at working concentrations of 20 µM  
** DNA nucleotides at a concentration of 10 mM 








Table 2.5 PCR amplification of GIF DNA 
Step Temperature (°C) Duration (seconds) 
Initial 98 30 
Denaturation * 98 10 
Annealing * 57 30 
Extension * 72 30 
Final extension 72 300 
* Denoted steps were repeated sequentially for 35 cycles 
After completion of PCR, 20 µL samples were visualised on a 1% agarose gel as 
described in 2.1.3.6 and imaged on a Gel Doc ™ XR+ imager (Bio-Rad). DNA was 
cleaned as described in preparation for restriction digestion, as described in 2.1.3.5. 
2.3.3 Restriction digestion of GIF insert DNA to produce sticky ends 
The amplified GIF insert DNA required restriction digests to remove buffering 
nucleotides (AAATTT) and produce sticky ends for insertion into pTT5. The 
reaction was set up as described in Table 2.6 and carried out as described in 2.1.3.2. 
Table 2.6 Reaction mix for restriction digestion of GIF construct DNA 
Reagent Volume (µL) 
EcoR1 1 
HindIII 1 
10x Buffer B 5 
Amplified GIF construct DNA* 4 
ddH2O 39 
Total volume 50 
* DNA at a concentration of 117 ng/µL 
After producing sticky ends, the GIF insert DNA needed to be isolated. The 
remainder of the sample was run on a 1% agarose gel as described in 2.2.2.3. The 
DNA of interest was excised and purified using the Freeze N’ Squeeze kit (Bio-Rad) 
as previously described in 2.2.2.9. At this point the GIF insert DNA was considered 
ready for ligation. 
2.3.4 Restriction digestion of pTT5 vector DNA 
Empty pTT5 plasmid was available in the laboratory. Before insertion of the GIF 
insert, pTT5 DNA needed to be digested to produce compatible sticky ends at the 
EcoRI and HindIII restrictions sites for the insertion of GIF DNA. The reaction was 
setup as described in Table 2.7 and carried out as described in 2.2.2.5. 
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Table 2.7 Reaction mix for restriction digest of pTT5 plasmid DNA 
Reagent Volume (µL) 
EcoR1 2 
HindIII 2 
10x Buffer B 5 
pTT5 plasmid DNA 4* 
ddH2O 39 
* pTT5 plasmid DNA was at a concentration of 475 ng/µL, approximately 2 µg DNA in total. 
Following restriction digestion, the DNA was purified as described in 2.2.2.2. 
2.3.5 Dephosphorylation of empty pTT5 vector DNA 
Reagents were pipetted into a microcentrifuge tube as described in Table 9. The 
reaction mix was mixed with care to ensure all reagents remained in contact at the 
bottom. This was incubated at 37 °C for 30 minutes; the reaction was stopped by 
incubating at 65 °C for 20 minutes to denature the dephosphorylase enzyme. 
Table 2.8 Reaction mix for dephosphorylation of pTT5 plasmid DNA 
Reagent Volume (µL) 
Dephosphorylase enzyme 2 
Dephosphorylase buffer 4 
pTT5 plasmid DNA 34 
 
The dephosphorylated and cut pTT5 DNA was isolated as described in 2.2.2.9 and 
cleaned as described in 2.2.2.2. 
2.3.6 Ligation of GIF insert DNA and pTT5 plasmid DNA 
Table 2.9 Reaction mix for ligation of pTT5 and GIF insert DNA 
Reagent Volume (µL) 
T4 DNA ligase (1 U/µL) 1 
10 x T4 DNA ligase buffer 2 
pTT5 DNA 1 
GIF insert DNA 6 
H2O 10 
Total volume 20 
*  GIF insert DNA concentration was 26.7 ng/µL 
**  pTT5 plasmid concentration was 400 ng/µL 
Reaction mix was pipetted into 1.7 mL tube. The tube was mixed carefully and 
centrifuged for 30 seconds at 500 g in a 5145R centrifuge (Eppendorf) using an FA-
45-24-11 centrifuge (Eppendorf)centrifuge using an A-4-81 rotor (Eppendorf) to 
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ensure all reagents were at the bottom of the tube. The tube was placed upright in a 4 
°C refrigerator and incubated overnight. 
2.3.7 Transformation of GIF-pTT5 DNA into DH5α 
50 µL aliquots of frozen DH5α cells were removed from storage at -80 °C and 
thawed on ice. 25 µL of thawed DH5α cells were removed and transferred to 1.7 mL 
microcentrifuge tube containing GIF construct DNA. This was incubated on ice for 
10 minutes. The cells were heat-shocked by holding the tube in a waterbath at 42 °C 
for precisely 90 seconds, the cells were then immediately returned to ice for 10 
minutes. 800 µL of LB was then transferred to the tube, which was incubated at 220 
RPM and 37 °C on an Innova® 2300 platform shaker (New Brunswick Scientific). 
After the incubation, the cell pellet and the supernatant were separated by 
centrifuging in an Eppendorf® 5415R centrifuge (Eppendorf) using a FA-45-24-11 
rotor (Eppendorf) at 12,000 g for 10 minutes. 750 µL of resulting supernatant was 
removed and discarded. The remaining cell pellet and supernatant was re-
homogenised in 200 µL of LB, before being streaked for single colonies on a LB-
agar plate. The plate was incubated overnight at 37 °C in a laboratory incubator 
(Axyos). 
2.3.8 Colony PCR  
Following ligation and streaking of plates, the resulting colonies were used to 
prepare plasmid DNA and run colony PCR (cPCR). Colonies were selected from the 
plate and smeared in the bottom of a PCR tube, and then used to inoculate an 
overnight culture. The PCR reaction mix was setup as described in Table 2.10 and 
run as described in Table 2.11. Twenty µL of the amplified DNA was mixed with 
bromophenol blue stain and run on a 1% agarose gel as described in 2.1.3.8. Samples 
that revealed a dense band at 858 bp were likely to have successfully taken up the 
GIF-pTT5 construct. Colony PCR has a high incidence of false-positives as some 
background GIF insert DNA was smeared over the agar-plate. For this reason it was 





Table 2.10 Reaction mix for colony PCR 
Reagent Volume (µL) 
10x Taq polymerase buffer 5 
Taq polymerase 1 
DNA nucleotides 3 
DMSO 1.5 
Template DNA n/a 
Forward primer 1 
Reverse primer  
H2O 37.5 
Total volume 50 
 
Table 2.11 Programme for colony PCR 
Step Temperature (°C) Duration 
1 - Initial 95 2 minutes 
2 - Denaturation * 95 30 seconds 
3 - Annealing* 57 30 seconds 
4 - Extension* 72 1 minute 
5 - Final extension 7 7 minutes 
* Denoted steps were repeated sequentially for 34 cycles. 
2.3.9 Confirmation of successful ligation and transformation 
Cell cultures corresponding to relevant colonies were removed from the -80 °C 
freezer and thawed. Plasmid DNA was obtained in small-scale preparation as 
described in 2.2.2.8. DNA was subject to PCR amplification and visualisation on a 
1% agarose gel and was also sent for sequencing at the Genetic Analysis Service at 
the University of Otago, as described in 2.2.2.4.  
Following identification of DH5α lineages that contained the GIF construct, large-
scale production plasmid DNA was required for expression in HEK 293-6E cells. 
This was achieved using the Qiagen megaprep kit as described in 2.2.2.6. DNA was 
quantified and the purity was checked as previously described in 2.2.2.7, as well as 
being visualised on a 1% agarose gel as described in 2.2.2.3.  
2.4 Expression and purification of the GIF protein 
2.4.1 Preparation of supernatant from HEK 293-6E cells 




2.4.2 Optimising day of harvest  
Supernatant was buffered using 5x GIF IMAC binding buffer and mixed thoroughly. 
The solution was filtered through a 0.45 µm RC filter and degassed for 20 minutes 
by vacuum. 
To determine optimal day of harvest post-transfection, five flasks of 40 mL HEK 
293-6E cells were each transfected with the mixtures set out in Table 2.12 and as 
described in 2.2.3.5. Beginning day two after transfection, one flask was harvested 
each day until day five. Two mL of cell mixture was transferred to a 2 mL 
microcentrifuge tube and centrifuged at 10,000 g for 20 minutes in a 5415R 
centrifuge (Eppendorf) using an FA-45-24-11 rotor (Eppendorf) at 4 °C. A western 
blot was used to detect GIF protein in the supernatant as described in  2.2.4.3.  
Table 2.12 Transfection mix for optimising day of harvest 
Reagent Volume  
PEI 132 µL 
DNA* 88 µL 
PBS 3.78 mL 
Total volume 4.00 mL 
 * DNA at a concentration of 500 ng/mL 
2.4.3 Optimising amount of DNA for transfection 
To determine the optimal amount of DNA used to transfect cells, eight flasks of 40 
mL HEK 293-6E cells were transfected using the mixtures set out in Table 2.13 and 
as described in 2.1.4.1. An additional flask of 40 mL HEK 293-6E cells was 
transfected with the GFP plasmid as a control. All samples were harvested three days 
post-transfection. 2 mL of cell mixture was transferred to a 2 mL microcentrifuge 
tube at centrifuged at 10,000 g for 20 minutes in a 5415R centrifuge (Eppendorf) at 4 
˚C using an FA-45-24-11 rotor (Eppendorf). GIF protein from the supernatant was 




















5.2 10.5 21.0 41.9 83.8 167.6 251.4 335.2 
PBS 
(mL) 3.86 3.86 3.85 3.83 3.78 3.7 3.62 3.53 
PEI 
(µL) 





2.4.3.1 Expression measured by western blotting 
Relative expression was initially tested by western blotting and compared against a 
known standard protein with a His-tag.  
A standard curve of His-tagged alanine racemase was produced by a 1 in 2 doubling 
dilution, resulting in standards of 0.500, 0.250, 0.125 and 0.063 mg/mL standards. 
The concentration of each standard was checked by Bradford Assay calibrated with a 
standard curve of BSA. The standards were run in duplicate and western blotted as 
described in 2.2.4.3 Excel (Microsoft) was used to construct a standard curve of 
protein concentration against signal intensity.  
Table 2.14 Creating alanine racemase standard curve 

















20 µL sample 




N/A 10 5 2.5 1.25 
 
Samples were prepared and transferred to mini-PROTEAN precast 4-20% (Bio-Rad). 
Gels were run for 40 minutes at 200 V as described in 2.2.4.1. One gel was stained 
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with Coomassie blue staining solution and destained with destaining solution as 
described in 2.2.4.2. The gel was imaged using a Gel Doc™ XR+ (Bio-Rad). 
The other gel was transferred to a PVDF membrane and western blotted and detected 
as described in 2.2.4.3.  
2.4.3.2 Expression measured by IMAC purification 
Table 2.15 Regimen for supplementing HEK 293-6E cells 
Contents PBS 
control 
VPA Peptone VPA and 
peptone 





VPA - 3.6 mM - 3.6 mM 
Peptone - - 0.5 % (w/v) 0.5 % (w/v) 
* GIF-pTT5 construct DNA at a concentration of 500 ng/µL 
Cells were transfected with the transfection mixtures described above and transfected 
as described in 2.2.3.5. 
Three days after transfection, cells were harvested as described in 2.2.3.6, before 
being buffered with 5x His-trap buffer, filtered through a 0.45 µm RC filter and 
degassed. 
The His-trap column was set up and prepared for purification. The control group was 
run through first, then cleaned with elution buffer before being re-equilibrated.  
1. Control supernatant 1 purified over His-trap column. The column was re-
equilibrated before control supernatant 2 was purified. 
2. His-trap column was stripped and recharged, and then re-equilibrated. 
3. Peptone supernatant 1 purified over His-trap column. The column was re-
equilibrated before control peptone 2 was purified. 
4. His-trap column was stripped and recharged, and then re-equilibrated. 
5. VPA supernatant 1 purified over His-trap column. The column was re-
equilibrated before VPA supernatant 2 was purified. 
6. His-trap column was stripped and recharged; and then re-equilibrated. 
7. Peptone and VPA supernatant 1 purified over His-trap column. The column 
was re-equilibrated before Peptone and VPA supernatant 2 was purified. 
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2.4.4 Stripping and recharging of His-trap FF crude 5 mL column 
Five mL crude His-trap FF was stripped and recharged according to the 
manufacturer’s instructions. 
2.4.5 IMAC purification  
The sample was loaded onto a 5 mL ff crude His-trap column (GE) using the sample 
pump. The column was washed with 12 column volumes (CV) of binding buffer 
before bound proteins were eluted across an imidazole gradient of 10-500 mM across 
20 CV into 3 mL fractions. 
2.4.6 Anion-exchange chromatography  
The sample was transferred to dialysis tubing with 10 kDa pores and dialysed against 
4 L of IEX buffer for 16 hours at 4 °C and 220 RPM. After dialysis the sample was 
centrifuged in a 5810R centrifuge (Eppendorf) using an A-4-81 rotor (Eppendorf) 
before the supernatant was injected onto a MonoQ 4.6 column. 
2.4.7 Dialysis with HSP70 removal buffer 
The sample was transferred to dialysis tubing with 10 kDa pores. The sample was 
immersed in HSP70 removal buffer (50 mM NaPO4, 150 mM KCl, 4 mM EDTA, pH 
6.9) and two charcoal ‘slugs’ were placed in the beaker. This was incubated at 4 °C 
at 220 RPM. The buffer was replaced after eight hours and left to incubate overnight. 
The sample was then dialysed in SEC buffer for SEC chromatography. 
2.4.8 SEC purification with HSP70 removal buffer 
The dialysed sample was centrifuged at 12,000 g for 20 minutes in a 5180R 
centrifuge to separate any aggregated protein and contaminants. 3 mL of supernatant 
was applied to a Superose 12 10/300 column (GE) by direct injection. The sample 
was eluted across 1.5 CV. 
2.5 Structure and binding behaviour of the GIF protein 
2.5.1 Prediction of glycosylation  
The FASTA sequence of the GIF protein was uploaded to prediction servers 
NetNGlyc 1.0 and NetOGlyc 4.0. Uniparc code for the GIF protein is Q9J5U5. 
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2.5.2 In vitro Deglycosylation of GIF 
GIF protein was concentrated to 100 µg in 30 µL (3.33 mg/mL) using an Amicon 
spin filter with 10 kDa pores. A control was setup in which 1 µL 5x incubation 
buffer was added instead of PNGaseF. 
Table 2.16 Reaction mixture for removing N-linked glycans 
Reagent Volume (µL) 
GIF Protein  30 
5x incubation buffer (Prozyme) 10 
Denaturation solution (Prozyme) 2.5 
 
The solution described in Table 2.16 was heated at 95 °C on a hotplate for 10 
minutes. The solution was left to cool to room temperature. One µL of PNGase F and 
2.5 µL of detergent solution were added to the solution. The solution was mixed 
gently and incubated in a 37 °C waterbath for 4 hours. Deglycosylated GIF was 
visualised by SDS-PAGE and stained with Coomassie blue, as described in 2.2.4.1 
and 2.2.4.2. 
2.5.3 In vivo deglycosylation of GIF  
Two flasks of 40 mL HEK 293-6E cells were transfected with GIF construct DNA as 
described in 2.2.3.5. An hour after transfection one flask was treated with 10 µg/mL 
tunicamycin dissolved in 0.1% DMSO, while the other was treated with 0.1% 
DMSO. After three days the sample was harvested as described in 2.2.3.6, and the 
pellet and cell-free supernatant were separated by centrifugation for 30 minutes at 
3,200 xg in a 5810R centrifuge (Eppendorf) using an A-4-81 rotor (Eppendorf).  
The pellets of each sample were lysed before analysis using mammalian protein 
extraction reagent (M-PER) (Thermo Fisher Scientific). One mL of M-PER was 
added per 100 mg of pellet. The control pellet (460 mg) was mixed with 4.6 mL, and 
the tunicamycin-treated pellet (360 mg) was mixed with 3.6 mL of M-PER. Samples 
were left on a roller in at 4 °C for 20 minutes. Samples were then centrifuged at 
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3,220 g in a 5810R centrifuge (Eppendorf) for 30 minutes using an A-4-81 rotor 
(Eppendorf). The supernatant was collected. 
The GIF protein was visualised by western blotting as described in 2.1.4.3. A sample 
from both the lysed pellet and supernatant were run on an SDS-PAGE gel and 
stained with Coomassie blue, while a duplicate gel was used for western blotting. 
2.5.4 Enzyme-linked immunosorbent assays 
Sandwich ELISAs were completed using kits purchased from BD and R&D. The 
workflow for each is similar; however, there are some minor differences and 
adaptations for each kit. The general protocol is described here, with details in the 
relevant section about each ELISA. 
1. Binding antibody (50 µL/well) applied to MaxiSorp™ 96-well plates (Nunc) 
and incubated overnight at 4 °C 
2. ELISA plate washed 
3. Plate blocked with 150 µL/well blocking buffer for two hours 
4. Experimental samples pre-bound on a 96-well plate at 37 °C and 200 RPM 
for 45 minutes 
5. ELISA plate washed 
6. Prebound samples were transferred to the ELISA plate. The plate was 
incubated for 2 hours 
7. ELISA plate washed 
8. Detection antibody applied to ELISA plate and incubated for two hours out of 
light 
9. Plate washed with washing buffer 
10. HRP-conjugate applied to plate and incubated for 20 minutes away from light 
11. Detection reagent (100 µL/well) applied to plate 
12. Reaction stopped with 50 µL/well 2N H2SO4   
13. Optical density at 540 and 570 nm measured on plate reader and analysed 
using SoftMax® Pro (molecular devices). 
2.5.4.1 ELISA with bIL-2 
A standard curve of bIL-2 was made using a 7-step doubling dilution producing 
standards of 100,000, 50,000, 25,000, 12,500, 6,250, 3,125 and 1,575 ng/mL. 
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2.5.4.2 ELISA with hIL-2 
A Bovine IL-2 DuoSet® kit (R&D systems) was used for the ‘sandwich’ ELISA 
with bIL-2 and GIF. A standard curve of bIL-2 was made using a 7-step doubling 
dilution in PBS, resulting in standards at 1,000, 500, 250, 125, 62.5, 31.75 and 15.75 
pg/mL. 
Test wells each contained 500 pg/mL hIL-2 (0.032 pM). GIF was diluted in a 16-step 
doubling dilution in PBS to achieve samples of 5000, 2500, 1250, 625, 312.5, 
156.25, 78.125, 39.063, 19.531, 9.766, 4.883, 2.441, 1.221, 0.61, 0.305 and 0.153 
ng/mL. 
The detection agent was diluted in PBS with 10% FBS. The assay was completed as 
per manufacturer’s instructions. 
Each sample was run in duplicate, this was repeated four times. 
2.5.4.3 ELISA with hGM-CSF 
A standard curve of hGM-CSF was made using a 7-step doubling dilution in PBS 
producing standards of 1,000, 500, 250, 125, 62.5, 31.25, 15.625 and 7.813 pg/mL.  
GIF was diluted in PBS in a 16-step doubling dilution producing standards of 2,000, 
1,000, 500, 250, 125, 62.5, 31.25, 15.625, 7.813, 3.906, 1.953, 0.977, 0.488, 0.244, 
0.122 and 0.061 ng/mL.  
Each sample was run in duplicate, with a technical replicate on the same plate. This 
process was repeated three times.  
2.5.5 Cell proliferation assays with TF-1 cells 
TF-1 cells were washed in PBS and diluted to 104 cells/mL in assay media. 200 µL of 
TF-1 cells in assay media were transferred to all wells in rows. In row A throughout 
all columns, 200 µL of appropriate growth media was added. The sample was serial 
diluted by pipetting down all rows. GIF and GM-CSF variants were co-diluted down 
appropriate columns, the purpose was to determine the ratio at which GIF reduces 
proliferation. 
The treatment groups were as follows: bGM-CSF control, bGM-CSF with GIF, 
hGM-CSF control, hGM-CSF with GIF, assay media control, assay media with GIF. 
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The exact solutions are described in 2.1.5. Each sample was tested in duplicate. The 
experiment was not able to be repeated. 
Table 2.17 Values used to calculate cell proliferation  
Value Description 
O1 Molar extinction coefficient of oxidized alamarBlue™ at 570 
nm -80586 
O2 Molar extinction coefficient of oxidized alamarBlue™ at 600 
nm - 117216 
A1 Observed absorbance of test well at 570 nm 
A2 Observed absorbance of test well at 600 nm 
P1 Observed absorbance of control well at 570 nm 
P2 Observed absorbance of control well at 600 nm 
 
The equation ‘((O2 x A1) – (O1 x A2)) / ((O2 x P1) – (O1 x P2)) x 100’ was used to 
determine % cell metabolism of test groups to control. The meaning of each variable 
is set-out in Table 2.17. The results were plotted on a graph using Prism version 8 
(GraphPad). 
2.6 In silico study of GIF binding behaviour 
2.6.1 Visualisation of protein sequence alignments 
To present data in a clear and concise manner, alignments were edited using ESPript 
3.0. Pre-aligned sequences were saved as ‘.aln’ files and uploaded for editing. 
Geneious was used to produce sequence consensus trees and calculate % similarity. 
Sequences were aligned using Clustal Omega version 1.2.2; sequences were grouped 
by similarity. The Jukes-Cantor model was used for distancing and the unweighted 
pair group method with arithmetic mean (UPGMA) was used as the tree building 
method. Data was resampled using the Bootstrap method.  
2.6.2 Visualisation of protein structure  
Visualisation of protein structure was completed using PyMOL (Schrödinger). 
Mutagenesis of specific protein residues involved replacing amino acids and 
selecting a rotamer, in each case the rotamer with least steric hindrance was selected. 
49 
 
2.6.3 Determining important residue mutations between GM-CSF variants 
Using data from Felix et al., (2016) a list of oGM-CSF residues involved directly in 
binding GIF was created. The primary protein sequences of oGM-CSF and hGM-
CSF were aligned, and variation of residues was noted. 
2.6.4 Determining important residues in IL-2 
Residues near the potential binding site between GIF and IL-2 were identified 
visually by looking at models of respective proteins on PyMOL. As GIF does not 
bind hIL-2, residue variations which could negatively affect binding were noted. 
2.6.5 Mutation modelling of GM-CSF residues  
Mutagenesis modelling was completed on PyMOL, with residues involved in binding 
GIF mutated along the interface. Rotamers for mutations were selected based on the 




3 Cloning, expression and purification of GIF 
 
This chapter describes the design and production of a GIF construct, expression of 
GIF in HEK-293-6E cells and subsequent purification. 
3.1 Cloning of the GIF construct 
3.1.1 Design of a GIF construct 
The GIF protein contains extensive glycosylation and disulfide bonds, necessitating 
expression in mammalian cells. Expression in mammalian cells required the design 
of a novel construct with additional features for purification. Once the construct and 
primers were designed, GIF-encoding plasmid DNA would be obtained by 
subcloning and transformation, as described in Figure 3.1. 
GIF was designed to be inserted into the MCS of pTT5 (Figure 3.2). SignalP-4.0 was 
used to detect an intrinsic secretion signal within the GIF protein primary sequence, 
seen in Figure 3.3. An S-score is given to each amino acid position as likelihood of 
being part of a secretion signal. In Figure 3.3, the S-score remains between 0.834 and 
0.948 between residues 1-19. The S-score for residue 19 is 0.900, which drops to 
0.487 for residue 20. The C-score indicates the amino acid most likely to be the first 
in the mature protein. Therefore, there should be a single peak at the position 
immediately after the secretion signal.  
In Figure 3.3 the highest C-score value is 0.829 at amino acid 20. The Y-score gives 
a high reading at a position which has both a high C-score value and a steep gradient 
of S-score values. In Figure 3.3 the highest Y-score value is 0.878 at position 20. The 
scores assigned by SignalP-4.0 indicated that GIF had an intrinsic secretion signal 
between residues 1-19, with the mature protein beginning with Ala20. An intrinsic 
secretion signal was predicted in the GIF protein (Figure 3.3, Table 3.1). 
As an intrinsic secretion peptide was present there was no need to encode one. The 
GIF insert DNA and primary protein sequence are displayed in Figure 3.4. The DNA 
sequence encodes an EcoRI site, a HindIII site, a Kozak sequence, a start codon, the 
GIF gene, a stop codon, a His-tag and a TEV-cleavage site. The DNA is in 5’ to 3’ 
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orientation to allow ligation into empty pTT5. Figure 3.4B displays the primary 
protein sequence encoded by the DNA insert.  
After the GIF construct was designed, forward and reverse primers were designed to 
allow the amplification of insert DNA for ligation into pTT5. The forward primer 
included 20 nucleotides starting from the 5’ end of the GIF sequence to allow 
binding to template DNA during PCR. An EcoRI restriction site and buffering 
nucleotides ‘AAATTT’ were added to the 5’ end of the sequence. The reverse primer 
included the reverse complement of 20 nucleotides from the 3’ terminus of the GIF 
DNA sequence. Nucleotides encoded a TEV-cleavage site, a hexahistidine tag (his-
tag) and a HindIII restriction site.  
OligoCalc (Kibbe, 2007) was used to check the melting temperature of primers, as 
well as to predict the chance of undesired secondary structure interactions. The 
nucleotide sequence of both the forward and reverse primer were uploaded to the 
server. Once the primers had melting temperatures within 1°C of each other and 








Figure 3.2 Schematic of the GIF construct Coloured arrows represent genes within the plasmid, 





Figure 3.3 GIF is predicted to have a secretion signal which is cleaved. GIF construct primary 
sequence in FASTA format was uploaded to SignalP4-0 servers. C-, S- and Y-scores were 
calculated for each amino acid residue in the construct. The score between 0 and 1.0 is indicated by 
colour-coded lines.  
 
Table 3.1 SignalP 4.0 predicted intrinsic secretion signal 
 
Measure AA Position Value Cut-off Signal peptide? 
Max C 20 0.829   
Max Y 20 0.878   
Max S 11 0.963   
Mean S 1-19 0.927   









Figure 3.4 GIF construct nucleotide and primary protein sequence. A) Sequence map of the GIF 
construct nucleotide sequences. The following features are annotated: EcoRI restriction site; Kozak 
sequence; start codon; intrinsic secretion signal; TEV cleavage site; His-tag; stop codon and HindIII 
restriction site. Other restriction sites intrinsic to the GIF sequence are annotated. B) The primary 
protein sequence of the GIF construct. The intrinsic secretion signal, TEV cleavage site and His-tag 
are annotated. Images generated using SnapGene®. 
 
3.1.2 PCR amplification of GIF insert DNA 
GIF insert DNA was obtained by PCR using the ‘EcoD’ plasmid as template DNA, 
as described in 2.3.2. The amplified DNA was run on an agarose gel, depicted in 
Figure 3.5. A single, clear band can be seen above the 850 bp marker. The GIF insert 
is 858 bp, indicating that the PCR was successful. The gene encoding glutamate 
racemase from Acinetobacter baumannii was used as a positive control for the 
agarose gel. The glutamate racemase gene is 864 bp.  
GIF insert DNA is the resulting product of PCR amplification of GIF template DNA 
using custom primers as described in 2.3.2. Phusion polymerase was used to amplify 




Figure 3.5 GIF insert DNA was amplified with high-fidelity DNA polymerase. The gel is 1% 
agarose with 0.5 µg/mL ethidium bromide in TAE buffer. 20 µL of GIF insert DNA (117 ng/µL) 
loaded. Ladder is 1 kb plus DNA ladder (Invitrogen). Positive control is glutamate racemase DNA 
from Acinetobacter baumannii (864 bp). 
 
3.1.3 Ligation and transformation 
Following successful PCR, the GIF insert was subjected to restriction digests to 
create sticky ends at EcoR1 and HindIII cut sites for ligation into pTT5 as described 
in 2.3.3. 
GIF insert DNA was ligated into pTT5 as described in 2.3.6. pTT5 had been digested 
to produce complementary sticky ends and dephosphorylated as described in 2.3.4 
and 2.3.6, respectively. 
Heat-shock competent DH5α cells were selected for subcloning as they have a high 
plasmid copy number. This was beneficial as DNA was required in large quantities 
for transient transfection. Heat-shock transformation was completed as described in 
2.3.7. 
Following transformation, the DH5α cells were plated on agar with ampicillin. The 
DH5α cells did not contain ampicillin resistance, while both the empty pTT5 plasmid 
and the GIF-pTT5 construct did. As both the GIF-pTT5 construct and the empty 
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plasmid contained an ampicillin resistance gene, selection-based verification 
methods would not work. Plasmid DNA was required for accurate DNA sequencing, 
the amplified insert DNA from colony PCR (cPCR) would not have been accurately 
sequenced due to background DNA. 
As there was no way to determine if the DH5α cells had taken up the GIF-pTT5 
construct or the empty pTT5 vector by looking at the colonies, colony PCR was done 
as a simple method of indicating which DH5α colonies had been successfully 
transformed with the GIF-pTT5 construct. 
Samples from 10 colonies following ligation and heat-shock transformation were 
selected and subjected to cPCR, as described in 2.3.8. A tooth-pick was used to 
smear bacterial colonies into PCR strip-tubes to act as the DNA template. The tooth-
pick was then used to inoculate starter cultures. The starter cultures were frozen for 
later analysis. 
An agarose gel of the samples can be seen in Figure 3.6. All colony PCR samples 
resulted in bands of varying intensity at the same size as the GIF insert DNA control, 
858 bp. The positive control was GIF insert DNA. Five samples with the most 
intense bands were selected for further analysis. This consisted of colonies, 5, 6, 7, 9 






Figure 3.6 GIF insert DNA was present in 10 colonies after cPCR. The gel is 1% agarose with 0.5 
µg/mL ethidium bromide in TAE buffer. Cell colonies grown after transformation were used to 
provide template DNA for PCR amplification using GIF insert primers. M is 1 kb plus DNA marker 
(Thermo Fisher Scientific). ‘+’ is the positive control, where linear GIF insert DNA was loaded. 
Colony DNA samples 1-10 were loaded and are labelled. The arrow indicates the theoretical size of 
the GIF insert fragment. 
 
Plasmid DNA of colonies 5, 6, 7, 9 and 10 was obtained by using a miniprep kit to 
extract DNA, as described in 2.2.2.8. Plasmid DNA quality was as described in 
2.2.2.7, before being sent for sequencing, as described in 2.3.9. A forward primer 
targeting the pTT5 MCS was used for sequencing. DNA was sequenced at Massey 
University using an ABI 3730xl DNA analyser. 
Figure 3.7 shows a segment of the chromatogram produced by sequencing plasmid 
DNA from colony 10. The chromatogram has sharp, concise base-calling peaks for 
each nucleotide. The background noise is low, and nucleotides can easily be called.  
The sequence produced by DNA sequencing was aligned against a reference 
sequence of the GIF construct, pictured in Figure 3.8. The DNA sequence of colony 
10 matches that of the GIF construct with 100% identities and 0 gaps. The quality of 
the sequencing chromatogram displayed in Figure 3.7 and the nucleotide sequence 
match in Figure 3.8 indicated that the GIF insert had been ligated into pTT5 and the 
DH5α cells had been successfully  transformed. BLASTn software (NIH) was used 
to align and present DNA sequences. The forward sequence of ‘Colony 10’ and GIF 
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construct reference sequence were submitted to Blastn (NIH) in FASTA format for 
alignment. 
Large-scale preparation of GIF construct plasmid DNA were completed using a 
Megaprep kit (Qiagen), as described in 2.2.2.6 
 
 
Figure 3.7 Chromatogram produced by DNA sequencing of plasmid DNA. Colony 10 plasmid 
DNA was subject to DNA sequencing at Massey University using an ABI 3730xl DNA analyser. 
Nucleotides 0-110 of the forward sequence are displayed. Chromatogram displayed on SnapGene® 









- The GIF construct was successfully produced in the lab 
- The construct was custom-made and subcloning was performed in-house 
- The construct was successfully ligated and transformed into heat-shock 
competent DH5α cells  
- Megaprep DNA plasmid preparation and isolation of GIF-pTT5 construct 
DNA provided both high yield and high-quality DNA for subsequent 
transfection into HEK 293-6E cells. 
3.2 Expression  
3.2.1 Confirmation of GIF expression 
GIF was initially expressed in non-adherent HEK 293-6E cells with 1 pg/DNA per 
cell, and harvested 5 days post-transfection, as described in 2.2.3.5. The total volume 
of HEK 293-6E cells was 800 mL. The supernatant was subsequently purified by 
IMAC using a His-trap column. Figure 3.9A displays selected fractions from the 
initial purification of GIF, which were subject to acetone precipitation. While all 
bands were still faint post-precipitation, one band appeared at 43 kDa, the size of 
glycosylated and secreted GIF (McInnes et al., 2005) between fractions A4-A8. 
Initial yield of GIF was low.  
Mass spectrometry (MS) was utilised to confirm the identity of the band. The band 
was excised from the gel and sent to the Centre for Protein Research at the 
University of Otago and analysed as described in 2.2.4.7. An image of the protein 
coverage is displayed in Figure 3.9B. The protein shared 39% coverage with the 
reference GIF construct sequence.  
While expression of the GIF protein was confirmed, the quantity was low, which was 
insufficient for further purification and experiments. To produce enough GIF for 






Figure 3.9 Confirmation of GIF protein expression after IMAC purification. A) Buffered 
supernatant from HEK 293-6E cells transfected with 1 pg/cell DNA of the GIF-pTT5 construct was 
purified by IMAC on a His-trap column. Selected samples from IMAC purification fractions by SDS-
PAGE. 4-20% SDS Mini-PROTEAN gels were used and visualised using Coomassie blue stain. 
Precision Plus Protein™ standard (Bio-rad) was used to estimate size of proteins. Samples from 
fractions A1-A8 were run. The arrow points to the predicted position of the GIF protein band. B) The 
putative GIF band was excised from the SDS-PAGE gel and sent to CPR for MS analysis. The 
detected fragments were compared to a reference primary sequence of the GIF construct, matching 




3.2.2 Optimising expression 
Based on evidence in the literature, parameters chosen for optimisation included day 
of harvest post-transfection, the amount of DNA used in transfection and the addition 
of supplements to cell culture (Longo et al., 2013).  
Five 40 mL sampkes of HEK 293-6E cells (1x106) were transfected with 1 pg/cell of 
the GIF-pTT5 construct in 250 mL flasks. The duration of expression was optimised 
by comparing GIF expression from cells harvested at different days post-transfection, 
described in 2.4.1.  
Samples of supernatant were visualised by western blotting, displayed in Figure 3.10. 
Each sample has clear and concise doublet bands at 43 kDa, which are not seen in the 
negative controls. In each lane, unidentified bands can be seen at 60 kDa and at a 
higher indistinguishable molecular weight. As the two unidentified bands are present 
in both the HEK 293-6E and GFP negative controls, it was decided that they were 
background noise. 
The band from the HEK 293-6E cell supernatant harvested three days post-
transfection appeared to be darker than the other samples. From here it was decided 
that transfected cells would be harvested three days post-transfection. 
 
Figure 3.10 Day 3 is optimal for harvesting cells. Supernatant of HEK 293-6E cells harvested at 
different days was subject to western blotting, a scan of the PVDF membrane is pictured above. 
Samples of supernatant harvested 2, 3, 4, 5- and 6-days post-transfection are included. HC is HEK 
293-6E cell mixture control. The GFP control serves as a negative control for His-tag targeted western 
blotting. MWM is Novex™ sharp pre-stained protein ladder (Thermo Fisher Scientific), molecular 
weights of marker bands are annotated. GIF protein band positions are indicated with an arrow. 
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The optimal amount of DNA to use in transfection was determined by comparing 
GIF expression between samples from HEK 293-6E cells transfected with different 
amounts of DNA as described in 2.4.1. The samples were visualised by western 
blotting, seen in Figure 3.11.  
GIF bands appear as doublets just above the 40 kDa marker in sample lanes; 
however, no clear bands can be distinguished in the 3x DNA sample. The GIF band 
cannot be seen in the GFP negative control. There are also unidentified bands at 60 
kDa and at a higher molecular weight through all samples and the negative control. 
These bands were also seen in Figure 3.10. There appeared to be no considerable 
difference in signal intensity between any of the varied DNA samples. 
It was concluded that altering the amount of DNA used in transfection produced no 
considerable difference within the parameters tested. Subsequent expression trials 
were conducted using the original DNA level of 1 pg DNA per cell. 
 
 
Figure 3.11 Altering amount of DNA in transfection. Supernatant of HEK 293-6E cells transfected 
with varying amounts of DNA was subject to western blotting. A scan of the PVDF membrane is 
pictured above. MWM is novex™ sharp pre-stained protein ladder (Thermo Fisher Scientific). 




3.2.3 Trialling cell supplementation 
Another expression trial was conducted to test whether: peptone; valproic acid 
(VPA) or peptone and VPA resulted in an increased expression of GIF compared to 
the PBS control. Peptone and VPA have been reported to increase protein expression 
in HEK 293 cells. 
Two separate experiments were performed. Both experiments were similar as they 
compared expression between the same treatment groups; however, some necessary 
changes were made depending on the method of quantification. The methods for 
measuring relative protein expression are outlined in Figure 3.12. 
- Relative expression between treatment groups measured by 
chemiluminescent western blotting 
- Relative expression between treatment groups measured by IMAC  
 
Figure 3.12 Description of two methods used to quantify expression. 
 
3.2.3.1 Developing a protocol for comparing expression 
The first method involved creating a standard curve of His-tagged alanine racemase 
by western blotting. The rationale was that supernatant from HEK 293-6E cells 
transfected with the GIF construct could be western blotted, allowing quick 
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quantification and comparison of GIF protein expression between treatment groups. 
The second method involved purifying the supernatant using IMAC and quantifying 
expression based on the size of peaks on the chromatogram. 
3.2.3.2 Comparing expression by western blot 
His-tagged alanine racemase standards were run on an SDS-PAGE gel, displayed in 
Figure 3.13. An SDS-PAGE gel ran in parallel was western blotted and signal 
intensity was used to construct a standard curve, as shown in Figure 3.14. In Figure 
3.13 clear and concise bands can be seen at 40 kDa. His-tagged alanine racemase 
does not undergo glycosylation and has a theoretical molecular weight of 41.748 
kDa. In wells containing 500, 250 and 125 µg/mL alanine racemase, two additional 
bands can be seen at just above and just below 80 kDa.  
The standard curve in Figure 3.14 had a linear relationship with an R2 value of 0.95 
between 1.5 and 10 µg of protein.  
While a standard curve had been setup, this method was not the most suitable for 
measuring the expression of GIF in the context of this project. The concentration of 
protein used is far higher than what would be expected from a GIF expression. 
 
Figure 3.13 SDS-PAGE of alanine racemase at known concentrations. His-tagged alanine 
racemase standards were diluted to 0.50, 0.25, 0.125 and 0.0624 mg/mL. The samples were loaded 
onto a precast 4-20% SDS gradient Mini-PROTEAN gel (Bio-rad). Marker is Novex (Thermo Fisher 
Scientific). Each lane containing alanine racemase samples was loaded with the same volume of 





Figure 3.14 Standard curve of His-tagged protein and signal intensity.Total protein amount (µg) is 
displayed on the x-axis, signal intensity (volume) is displayed on the y-axis. Error is displayed as 
standard deviation (SD). 20 µL of 500, 250, 125 and 61.5 µg/mL alanine racemase protein was loaded 
onto an SDS-PAGE gel in duplicate. The total protein load for each sample group was 1.25, 2.5, 5 and 
10 µg, respectively. The gel was western blotted and the mean average signal intensity for each 
duplicate recorded. R2 value is 0.95. 
3.2.3.3 Relative expression measured by purification chromatography  
Another method of comparing expression between treatment groups was explored. 
Instead of preparing a standard curve and quantifying protein directly, it involved 
treating cells under control conditions, with VPA, with VPA and peptone and with 
peptone. The supernatants were harvested and purified on a His-trap column, with 
absorbance peaks used to indicate relative expression. The methodology is detailed 
in 2.4.3.2. 
The mean average height of peaks corresponding to different treatment groups are 
listed in Table 3.2. The control treatment resulted in an average peak height of 59.23 
mAu, peptone averaged 58.77 mAu, VPA averaged 46.01 mAu and VPA and 
peptone duo-treatment averaged 52.15 mAu. 
The results indicated that the control group resulted in the highest average peak size, 
although it was less than 0.5 mAu more than peptone. VPA and peptone and VPA 
resulted in lower peaks than the control group.  
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While the control group had a slightly higher average peak size than peptone 
treatment, it was decided to use 0.5% peptone supplementation in future.  
It was ultimately decided that subsequent transfections would use 1 pg/cell GIF 
construct DNA, be treated with peptone and harvested three days post-transfection. 
 
Figure 3.15 IMAC chromatograms of different treatment groups. Chromatograms produced by 
IMAC purification of the four different treatment groups are displayed above. A) control; B) peptone; 
C) VPA; D) peptone and VPA. The chromatograms are show the absorbance at 280 nm trace of 
elution between 220 and 290 mL. 
Table 3.2 Average peak size from differential cell feeding 










3.2.4 Summary  
- Harvesting transfected cells 3 days post-transfection resulted in the highest yield of 
GIF 
- Transfecting cells with a range of different amounts of DNA made no difference to 
expression  
- Feeding cells with 0.5 %(w/v) peptone resulted in increased expression, while 
feeding with 3.6 mM VPA reduced yield.  
3.3 Purification of the GIF protein 
After expression was optimised, a purification protocol was established using an 
ÄKTA™ purifier (General Electric). FPLC purification was a multi-step procedure 
using different chromatography columns, each separating GIF from other proteins 
based on its biochemical properties. Finally, heat-shock protein 70 (HSP70) was 
separated from the GIF protein. This process has established a ‘pipeline’ for GIF 
production, resulting in abundant and pure protein for experimentation. 
3.3.1 IMAC 
The GIF construct was engineered to contain an N-terminal his-tag, allowing 
purification by affinity chromatography. A 5 mL His-trap FF crude column 
containing a resin of nickel Superose 6 fast-flow was used for this step. Nickle 
Superose 6 fast-flow resin is composed of highly cross-linked agarose which binds 
histidine residues on the surface of proteins. Proteins without a His-tag should not 
bind the column, although some contaminant proteins contain intrinsic repeats of 
histidine which allows column binding. The washing buffer used in IMAC 
purification of GIF contained 10 mM imidazole, which reduces non-specific protein 
binding. Proteins were eluted across an imidazole gradient, which has an affinity for 
the nickel resin. 
Cell supernatant from HEK 293-6E cells transfected with the GIF-pTT5 construct 
was purified by IMAC. One litre of buffered and filtered supernatant was loaded 
onto the column using a P90 sample pump. After sample was loaded the column was 
washed with 12 CV of IMAC buffer A.  
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The chromatogram is displayed in Figure 3.16A, where the A280 trace has a sharp 
peak of 100 mAu at 16% imidazole. The peak drops and plateaus at 20% forming a 
shoulder ending at 30% imidazole. The absorbance drops to 20 mAu at 45% 
imidazole, before plateauing again. The absorbance remains near 10 mAu until the 
end of the elution.  
Fractions corresponding to the peaks were analysed by SDS-PAGE, displayed in 
Figure 3.16B. A blurry band at 43 kDa can be seen throughout elution, peaking in 
intensity between fractions A6 to A12. All other bands represent contaminant 
protein, necessitating additional purification steps. 
It was decided to pool fractions A3 to B8 to maximise the amount of GIF protein. A 
Bradford assay indicated that the pooled 54 mL sample had a concentration of 0.09 




Figure 3.16 Chromatogram of GIF elution after IMAC. A) The chromatogram of absorbance at 
280 nm of the solution eluted between 0- 500 mM imidazole. The blue trace is absorbance, while the 
red line indicates the gradient between 0-100% buffer B. B) is an SDS-PAGE gel of selected fractions 
corresponding to the absorbance peak in Figure 3.16A. MWM is Precision Plus (Novex). Individual 
marker bands are annotated. 
 
3.3.2 Size exclusion chromatography and identification of HSP70 
Size-exclusion chromatography was used as a polishing step to separate GIF and 
HSP70. A Superose 12 10/300 GL column (General Electric) was used. Larger 
proteins flow through the column faster, while smaller molecules are more likely to 
interact with the resin and are eluted later. HSP70, the putative GIF dimer and the 
GIF monomer have molecular weights of 70, 86 and 43 kDa, respectively. 
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The pooled fractions from IMAC were dialysed in SEC buffer for 16 hours before 
being concentrated to 2 mL for SEC. The sample was injected onto a Superdex 75 
column and eluted over 1.2 column volumes into 3 mL fractions 
A single well-defined absorbance peak can be seen between fractions B1 and B5 
(Figure 3.17A). In SDS-PAGE analysis (Figure 3.17B), fraction B3 contains a clear, 
thick band near 44 kDa. Previous SDS-PAGE and MS analysis have confirmed that 
this is the GIF protein. Another intense band can be seen near 70 kDa, and another 
two fainter bands can be seen above 75 kDa, and below 150 kDa. 
MS analysis was used to identify the protein that co-eluted with GIF and could be 
visualised near 70 kDa, as depicted in Figure 3.17B. MS analysis matched the 
protein with human heat-shock protein 70. In Figure 3.18 the MASCOT search result 
is shown. The detected peptides shared 39% coverage with HSP70. 
The presence of HSP70 was problematic as it may have interfered with downstream 







Figure 3.17 Initial SEC purification of the GIF protein. A) The chromatogram is the absorbance at 
280 nm between 0 and 200 mL of retention volume. B) Fractions A12, B1, B3, B4 and B5 were 
analysed by SDS-PAGE using 4-20% SDS Mini-PROTEAN gels (Bio-rad). The arrow points to the 
GIF protein, and the unknown protein of interest is highlighted in red. This band was excised and 




Figure 3.18 Identification of HSP70 by mass spectrometry. A band at the 70 kDa marker in Figure 
3.17 was excised from the SDS-PAGE gel and sent for MS analysis at the Otago Centre for Protein 
Research. The detected peptides were searched in the MASCOT database. The aligned protein 
sequence of heat-shock protein 70 and detected peptides are shown here. Matching peptide are 
displayed in bold red. 
 
3.3.3 Anion-exchange chromatography  
GIF has a net anionic charge with a calculated pI of 6.75. Anion-exchange 
chromatography was used to separate proteins by their net charge. A Mono Q™ 
4.6/100 PE column (General Electric) was used for IEX. Mono Q columns contain a 
strongly cationic resin made up of Q MonoBeads® (General Electric), which would 
bind the GIF protein. Proteins were separated on a salt gradient. As the salt 
concentration increases, the negatively charged Cl- compete with bound proteins to 
bind the cationic resin. As GIF is weakly anionic, it was anticipated to elute early in 
the gradient. Contaminant proteins with a net cationic charge would be excluded 
from binding the column, while anionic proteins will be separated into separate 
fractions. Bound proteins were eluted across a gradient of 0-1000 mM sodium 
chloride over 40 CV (78 mL). 
75 
 
Following the discovery of HSP70, a new purification protocol was devised with a 
specific step to separate GIF from HSP70. A new batch of HEK 293-6E cells was 
transfected with the GIF-pTT5 construct and purified by IMAC as previously 
described. An additional IEX step was added, the chromatogram and gel of selected 
fractions can be seen in Figure 3.19. Selected fractions from IMAC purification were 
pooled, concentrated and dialysed in IEX buffer. The sample was loaded onto a 
MonoQ column and eluted across a gradient of 0-1000 mM NaCl. A biphasic peak 
can be seen between 80-100 mL, peaking at 39 mAu at fraction C2.  
Fractions corresponding to the absorbance peaks were visualised by SDS-PAGE, 
seen in Figure 3.19B. Dark bands corresponding to the GIF protein can be seen in 
fractions B4 to C6. A band corresponding to HSP70 can be seen throughout the 







Figure 3.19 Anion exchange chromatography of GIF. A) is the absorbance at 280 nm detected 
across the elution gradient. B) Fractions corresponding to the absorbance peak were visualised on a 4-




3.3.4 Size exclusion chromatography and removal of HSP70 
Following overnight dialysis with HSP70 removal buffer, selected fractions were 
further purified by SEC. The chromatogram and a gel of selected fractions are 
displayed in Figure 3.20. An absorbance peak can be seen at 12 mL with a maximum 
absorbance of 22 mAu. The peak drops to 3 mAu at 16 mL. A second peak has a 
maximum absorbance of 7 mAu at 19 mL. Fractions from across the chromatogram 
were visualised by SDS-PAGE. Fractions A5-A8 correspond to the initial absorbance 
peak. Each fraction contains the GIF protein. A light HSP70 band can be seen in 
fraction A5 and A6. Fractions B3, B4, B5 correspond to the plateau between the two 
peaks and contain no visible bands. Fraction C1 corresponds to the second peak and 
has no visible bands. 
As the GIF protein and HSP70 appeared in separate fractions and no other bands 
were visualised, GIF was considered pure. Table 3.3 summarises the yields and 
losses of total protein at each step of purification. 144 µg of pure GIF was the yield 
from expression and purification, representing 3.48% of total protein detected after 




Figure 3.20 Separation of HSP70 from the GIF protein. A) chromatogram from SEC purification of 
sample treated with EDTA and AC. Samples were eluted over 1.5 column volumes. B) 4-20% SDS 
mini-PROTEAN gel loaded with fractions from SEC purification corresponding to mAu peak. MWM 
is Precision Plus Protein™ standard (Bio-rad). 20 µL of sample not treated with EDTA and AC 
loaded as a control and labelled as ‘pre-dialysis’. Fractions from SEC purification are labelled above 
gel. GIF and HSP70 bands are indicated with arrows.
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Volume (mL) Total protein 
(mg) 
% of total 
IMAC 0.090 54 4.3 100 % 
IEX 0.029 26 0.75 17.44 % 
SEC 0.039 4 0.144 3.48% 
*Protein concentration includes contaminants which are removed throughout purification. 
 
Figure 3.21 Schematic of optimised purification protocol to yield pure GIF. This image depicts the 
optimised GIF purification protocol utilising IMAC, IEX, dialysis with HSP70 removal buffer and a 




- A step-wise expression and purification protocol was established to maximise 
yield of pure GIF protein 
- Optimised expression parameters included: 
• Transfecting with 1 pg DNA per cell 
• Harvesting 3 days post-transfection 
• Supplementing transfected cell mix to 0.5% (w/v) N1 peptone 24 
hours post-transfection 
- GIF was found to coelute with HSP70, even after IMAC and SEC 
- A 3-step FPLC purification was established to purify the GIF protein. This 





4 The structure and binding behaviour of GIF 
 
This chapter describes the verification of GIF structure and binding behaviour. The 
GIF protein is subject to N-linked glycosylation, which is required for secretion from 
the cell. Sandwich ELISAs determined that GIF cannot bind hGM-CSF or hIL-2, but 
it can bind bIL-2. Cell proliferation assays with GM-CSF dependent TF1 cells 
indicated that GIF may be able to form a transitory interaction with hGM-CSF. 
4.1 Glycosylation of the GIF protein 
GIF has been reported to undergo extensive N-linked glycosylation as discussed in 
1.3.8. The glycosylation is depicted in Figure 4.1, where glycan units can be seen 
along the backbone of the GIF protein. Glycosylation can be heterogeneous 
depending on the method of protein expression (Higel et al., 2016). Other 
publications have expressed GIF in Chinese hamster ovary (CHO) cells and HEK 
293-T cells, so it was decided to determine whether GIF underwent the same 
glycosylation using our HEK 293-6E system. Glycosylation was predicted using 
NetNGly 1.0, before GIF was deglycosylated in vitro with PNGase F and in vivo 
with tunicamycin. 
Asn-linked glycosylation of GIF was visualised by protein modelling using the x-ray 
crystal structure of GIF which had been previously determined. This is shown in 
Figure 4.1. Glycan units are coloured red, and a total of six sites on the GIF dimer 
are glycosylated. The glycan units sit on one plane of the GIF structure, opposite 





Figure 4.1 Visualisation of Asn-linked glycosylation present on the GIF dimer. Image generated 
using PyMOL version 2.1 (Schrödinger) using PDB file 5D28. Dimeric GIF is coloured blue while 
glycan units are coloured red. 
 
4.1.1 Prediction of glycosylation 
Asn-linked glycosylation of the GIF construct was predicted using NetNGlyc version 
1.0, the results are displayed in Figure 4.2.  
The predicted Asn-linked glycosylation of GIF predicted that residues 30, 36, 63 and 
115 would be glycosylated. Three of these residues; Asn 30, 36 and 63 have been 
reported to be glycosylated (Felix et al., 2016), while Asn 115 was not. Interestingly, 
Asn 115 had a higher jury score for glycosylation of 9/9. Despite the predicted 
additional glycosylation site, the GIF construct was visualised at 43 kDa, the same 
size as other reports (Figure 3.10) (Felix et al., 2016; McInnes et al., 2005). If there 
was an additional glycosylation site, GIF would likely appear as a larger protein. 
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It was decided to investigate Asn-linked glycosylation of the GIF protein by 
removing glycans, as well as by preventing glycosylation in vivo and examining the 
effects of cellular secretion. 
 
Figure 4.2 Prediction of N-linked glycosylation. A) The GIF protein FASTA sequence was uploaded 
to the NetNGly 1.0 server. Each Asn residue is given a score based on the identity of neighbouring 
residues, those that cross the 0.5 threshold are indicated as a green line. B) Score values for the four 
Asn residues that reach the threshold score for likely glycosylation. 
 
O-linked glycosylation was predicted using NetOGlyc version 4.0, the results are 
displayed in Figure 4.3. Residues 252 and 253 were assigned #positive, indicating a 
potential O-linked glycosylation site. GIF has previously been reported not to 
undergo O-linked glycosylation, the size of the GIF protein in our expression studies 
also did not reflect the size that might be expected form additional glycosylation. It 





Figure 4.3 Predicted O-linked glycosylation within the GIF protein. The GIF protein FASTA 
sequence was uploaded to NetOGly 4.0 server. All Ser and Thr residues were given a score based on 
the identity of neighbouring residues. Ser and Thr residues given a score above 0.5 are flagged as 
‘#positive’. 
4.1.2 Removing N-linked glycan units 
N-linked glycan units were removed using PNGaseF as described in 2.5.2. The 
resulting samples were visualised by SDS-PAGE gel, depicted in Figure 4.4. 
In lane 1 (GIF treated with PNGaseF), two bands appear between 25 and 37 kDa. 
Both bands are clear and concise. Control GIF can be seen in lane 2. A blurred band 
can be seen at 43 kDa. The theoretical mass of PNGaseF is 34.78 kDa, while the GIF 
construct is predicted to be 31.39 kDa. This indicated the GIF protein has been 
deglycosylated and appears in close proximity to PNGaseF in the SDS-PAGE gel, 
while control GIF appeared at 43 kDa. 
It was concluded that N-linked glycans were removed from the GIF protein, resulting 
in a decreased molecular weight of 12 kDa. As the band representing deglycosylated 
GIF is concise, while the glycosylated GIF is blurry, it was decided that the blurred 




Figure 4.4 In vitro deglycosylation of GIF under denaturing conditions. GIF protein was treated 
with PNGaseF to remove N-linked glycosylation under denaturing conditions. The control was GIF 
that was treated with denaturation buffer but not PNGase F. The deglycosylated GIF and a GIF 
control were loaded onto a 4-20% SDS Mini-Protean® gell. Lane 1 contains GIF treated with 




4.1.3 Preventing N-linked glycosylation in vivo 
To determine the necessity of glycosylation on GIF secretion, tunicamycin was used 
to prevent protein glycosylation in vivo as described in 2.5.3. Two flasks containing 
40 mL of HEK 293-6E cells were transfected with the GIF-pTT5 construct. An hour 
post-transfection, one was treated with tunicamycin and the other with a DMSO 
control. Cell supernatant and pellet samples were run on SDS-PAGE and western 
blotted.  
The western blot is displayed in Figure 4.5. In the DMSO cell pellet, a band can be 
seen at 40 kDa, while a band near 44 kDa can be seen in the supernatant. The band in 
the supernatant at 43 kDa likely represents fully glycosylated GIF, while the 40 kDa 
band in the pellet represents partially glycosylated GIF. 
In the tunicamycin-treated pellet, a band can be seen just above 30 kDa; however, 
there are no visible bands in the supernatant
 
Figure 4.5 Deglycosylation of the GIF protein in vivo using tunicamycinWestern blot image of 
samples from the pellet and supernatant of control cells and cells treated with tunicamycin. The pellet 
‘P’ and supernatant ‘S’ of cells treated with either DMSO or tunicamycin are labelled above.MWM is 
Novex (Thermo Fisher Scientific). 
4.1.4 Summary  




- N-linked glycans were removed with PNGase F, reducing the molecular 
weight of GIF by nearly 12 kDa 
- Tunicamycin appeared to prevent glycosylation of GIF in vivo, non-
glycosylated protein was not secreted from the cell.  
4.2 The interaction between GIF and IL-2 
4.2.1 bIL-2 ‘sandwich’ ELISA 
Sandwich enzyme-linked immunosorbent assays were used to gain an indication of 
the binding affinity of GIF to cytokine variants. A standard curve of appropriate 
cytokine and absorbance at 450 nm was created. Standards of GIF were mixed with a 
cytokine standard and the plate was read at 450 nm. The concentration of unbound 
standard was determined using the standard curve. A reduction in detected cytokine 
would indicate that it had been bound by the GIF protein. 
GIF has been reported to bind both bovine IL-2 and GM-CSF (McInnes et al., 2005). 
It was decided to initially examine the binding of GIF to bIL-2 using a wide molar 
range of both GIF and bIL-2, as described in 2.5.4.1. 
A graph with results from the ELISA is displayed in Figure 4.6. As the molar 
concentration of GIF increases, the concentration of unbound bIL-2 decreases. The 
reduction in detected bIL-2 is greatest between 0.01 and 10 pM of GIF, after which 
the level plateaus. Despite an overwhelming molar ratio of GIF:bIL-2, bIL-2 is still 
detected. This was unexpected and may indicate an issue with the experimental 




Figure 4.6 bIL-2 sandwich ELISA. bIL-2 was mixed with a range of GIF standards and unbound 
bIL-2 was quantified against a standard curve. Error is presented as standard deviation (SD).  
 
4.2.2 hIL-2 ‘sandwich’ ELISA 
GIF has been reported not to bind hIL-2 (McInnes et al., 2005). A ‘sandwich’ ELISA 
was setup to examine the binding behaviour of our GIF construct with hIL-2. A 16-
step dilution series of GIF was used to test a wide range of GIF concentrations, as 
described in 2.5.4.2.  
A graph with the result is displayed in Figure 4.7. The concentration of unbound hIL-
2 does not reduce with any molar concentration of GIF. The concentration of 
unbound hIL-2 appears to increase slightly at higher concentrations of GIF. An 
increased level of hIL-2 would be impossible as each well had the same standard of 
hIL-2. 
It was concluded that GIF does not bind hIL-2, and that the increased levels of hIL-2 




Figure 4.7 hIL-2 sandwich ELISA. hIL-2 was mixed with a range of GIF standards. Unbound hIL-2 
was quantified against a standard curve. Error is presented as standard deviation (SD). 
 
4.2.3 Summary 
- GIF bound bIL-2 in a ‘sandwich’ ELISA, although the binding pattern was 
unusual 
- GIF did not bind hIL-2 in a ‘sandwich’ ELISA. 
4.3 The interaction between GIF and GM-CSF 
4.3.1 hGM-CSF ‘sandwich’ ELISA 
GIF has been reported not to bind hGM-CSF (McInnes et al., 2005). A ‘sandwich’ 
ELISA was setup to examine the binding behaviour of our GIF with hGM-CSF. A 
16-step dilution series of GIF was used to test a wide range of GIF concentrations, as 
described in 2.5.4.3. 
A graph with the results is displayed in Figure 4.8. The concentration of unbound 
hGM-CSF fluctuates across the range of GIF concentrations tested, peaking towards 
the middle of the range before returning to baseline.  
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This result was likely due to experimental error. It was decided to further investigate 
the interaction of GIF and hGM-CSF using a cell proliferation assay. 
 
Figure 4.8 hGM-CSF sandwich ELISA. Depicted here is a ‘sandwich’ ELISA of GIF and hGM-
CSF. The molar concentration of unbound hGM-CSF is set on the y-axis, while the molar 
concentration of GIF tested is displayed in the x-axis. Unbound hGM-CSF was quantified against a 
standard curve. Error is presented as standard deviation (SD).  
 
4.3.2 TF1 cell proliferation assay 
A cell proliferation assay using TF-1 cells was used to detect any binding between 
GIF and hGM-CSF. TF-1 cells are derived from a human cancer which uses GM-
CSF as a growth factor. The rationale behind the experiment is that cells treated with 
GM-CSF would have a higher proliferation than cells treated with assay media. The 
interaction of GIF with GM-CSF was measured by also treating cells with GM-CSF 
and GIF. If GIF did bind GM-CSF the proliferation rate of those cells would be 
lower than the cells treated with only GM-CSF. The assay and interpretation 
methodology are described in 2.5.5. 
The ratio of GIF to GM-CSF is constant throughout the assay. The purpose of this 
was to determine if the results were more obvious at a certain ratio, which would be 
used in subsequent experiments. AlamarBlue® was used to measure cell 
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proliferation. AlamarBlue® contains resazurin, a non-toxic blue dye which is 
reduced to resofurin, a pink colour, by cell metabolism. The colour change can be 
detected by measuring the absorbance which can be used to directly compare 
metabolism between samples. 20 µL of AlamarBlue® was pipetted into each well. 
Plates were shaken gently before being returned to the incubator. The absorbance at 
570 and 600 nm was measured 24 hours after the addition of AlamarBlue®. A 
schematic describing the experiment is displayed in Figure 4.9.  
Graphs of cell proliferation are displayed in Figure 4.10. GIF reduced the 
proliferation of TF1 cells treated with hGM-CSF and hGM-CSF (Figure 4.10A, 
Figure 4.10B). GIF treatment reduced the proliferation of cells treated with bGM-
CSF more than those treated with hGM-CSF. 
It was expected that the proliferation of cells treated with bGM-CSF would be 
reduced, as GIF is known to bind bGM-CSF. The reduced proliferation of cells 











Figure 4.10 TF-1 cell proliferation assay. A) % cell proliferation of cells treated with hGM-CSF. B) 
The % proliferation of cells treated with bGM-CSF. Cell proliferation measured by measuring A570 





- GIF did not bind hGM-CSF in a ‘sandwich’ ELISA 
- GIF reduced the proliferation of both TF-1 cells fed with hGM-CSF and 
bGM-CSF 





5 In silico examination of GIF structure and binding 
behaviour 
 
This chapter describes an examination of a theoretically possible GIF complex with 
human GM-CSF. The structure of the GIF-hGM-CSF complex is modelled on the 
GIF-oGM-CSF complex. A hypothesis is put forward to explain a possible transitory 
interaction between GIF and hGM-CSF. The structural properties of IL-2 and GIF 
are modelled to explore a potential GM-CSF binding site. 
5.1 Structural basis for GIF-GM-CSF complex formation 
In Chapter 4 it was determined that GIF did not bind either human IL-2 or human 
GM-CSF in ELISAs; however, GM-CSF dependent TF-1 cells treated with GIF had 
reduced proliferation compared to the no-GIF control. These results were unexpected 
as GIF has been reported to not bind human GM-CSF or IL-2. In Felix et al. (2016) 
in which the GIF-oGM-CSF structure was first reported, there was limited 
explanation of what prevented GIF from also binding hGM-CSF. In this chapter, 
modelling is used to examine the structural basis of the binding of GIF to oGM-CSF 
and to probe the potential for binding to occur between GIF and hGM-CSF. The 
structural basis of the GIF-IL-2 complex is also examined. 
5.1.1 Sequence variation between GM-CSF homologs  
The capacity of proteins to interact with other proteins is largely dependent on the 
structure of each protein. As the primary sequence is the basis of overall protein 
structure, sequence homology can be used to gain an indication of the functional 
similarities between proteins. 
Human GM-CSF shares primary sequence homology with ovine, bovine and murine 
GM-CSF, with identities of 80.56%, 70.14% and 54.86%, respectively. Despite 
variation in sequence identity, amino acids were similar. In Figure 5.1 the sequences 
of human, ovine and bovine GM-CSF are aligned. The homologs share sequence 
identity, with ovine and bovine sharing the most identities. Murine GM-CSF is most 
dissimilar from the other homologs. Murine GM-CSF has been reported to not bind 
GIF (Deane et al., 2000). 
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The aligned sequence of ovine and human GM-CSF is displayed in Figure 5.2. 
Residues involved in complex formation with GIF are denoted with an arrow. Of the 
16 residues involved in binding, seven have been substituted. The presence of 7 
substituted residues on the hGM-CSF binding interface with GIF may help to explain 
why GIF did not bind hGM-CSF in 4.3.1 and in the literature (Felix et al., 2016; 
McInnes et al., 2005). 
Sequence similarity is highest between ovine and bovine GM-CSF. Figure 5.3 
depicts the similarity between human, ovine and bovine GM-CSF.  
 
 
Figure 5.1 Sequence identity of GM-CSF homologs. Conserved residues displayed as white letters 
with red backgrounds. Where there is no consensus letters are black with no background colour. 
Where there is a majority consensus/similarity the position has a black outline, identical/similar 
residues are coloured red, while the dissimilar variant is coloured black. Secretion signal peptides 





Figure 5.2 Sequence identity between ovine and human GM-CSF. Conserved residues displayed as 
white letters with red backgrounds. Consensus sequence is displayed below, a ‘.’indicates no match, 
while ‘!’ indicates a similar residue, Alignment file rendered on ESPript 3.0. Residues involved in 




Figure 5.3 Consensus and sequence similarity between GM-CSF variants. A) A consensus tree of 
primary sequence identity between human, ovine, bovine and murine GM-CSF. B) Similarity table of 
Amino acid sequences of GM-CSF variants. Sequences aligned using Clustal Omega version 1.2.2. 
Consensus tree produced using UPGMA method. Displayed amino acid similarity % calculated by 
Blosum 45 with threshold of value 1. All % values rounded to two decimal places. 
 
5.1.2 Modelling a human GM-CSF-GIF complex 
In 5.1.1 it was determined that seven amino acid residues involved in GIF complex 
formation were substituted between human and ovine GM-CSF variants. The next 
step was to determine which GIF residues were affected by the mutation, and the 
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effect this would have on binding. Table 5.1 contains a list of substituted residues 
involved in complex formation, both hydrogen bonds, VDW contacts and 
electrostatic interaction.  
An hGM-CSF complex was modelled using the structure of the GIF-oGM-CSF 
complex, as described in 2.6.5. Table 5.1 contains a list of amino acid substitutions 
between human and ovine GM-CSF. Some substitutions appeared unlikely to make a 
significant difference in binding, for example Ile116val, as the amino acids differ by 
only one carbon group.  
Substitutions where an amino acid gained or lost a property were more likely to 
prevent complex formation. It is important to note that while Ile116val was unlikely 
to ameliorate complex formation independently, it is directly next to a Phe115Leu 
mutation, as well as four residues involved in complex formation (Figure 5.2). Each 
substitution would likely require the GIF protein and hGM-CSF to undergo 
conformational change to accommodate the change in biochemical properties. The 






Table 5.1 GM-CSF residue substitutions  
Substitution Ovine GM-CSF properties   Human GM-CSF 
properties 
Hydrogen bonds   
D17N Negative charge Polar uncharged 
K20Q Positive charge Polar uncharged 
L23R Non-polar Positive charge 
F115L Aromatic group No aromatic group 
I116V Non-polar Slightly smaller sidechain 
VDW contacts   
Q14E Polar uncharged Negative 
K20Q Positive charge Polar uncharged 
L23R Non-polar Positive charge 
S24R Polar uncharged Positive charge 
Salt bridges   
D17N Negative charge Polar uncharged 
 
GIF residue Lys211 is essential for binding oGM-CSF. A mutagenesis experiment 
using Lys221Ala has been reported to have 137-fold lower affinity for oGM-CSF 
complex formation (Felix et al., 2016). A model of GIF in complex with oGM-CSF 
and a theoretical model of GIF in complex with hGM-CSF is presented in Figure 5.4  
Lys211 forms hydrogen bonds with three oGM-CSF residues; Leu114, Phe115 and 
Ile116. It also has VDW contacts with Ile19 and Leu23. 
hGM-CSF has a Phe115Leu substitution, which loses the presence of the aromatic 
ring of phenylalanine. This, coupled with the Ile116Val mutation between the 
binding residues, could present a sterically unfavourable binding space for hGM-CSF 
to bind the K211 of GIF.  
hGM-CSF also has a Leu23Arg substitution. While Lys211 would form a VDW 
contact with Leu23, in hGM-CSF there is a large positive sidechain in the vicinity of 
where Lys211 and His232 would form bonds. The interaction is displayed in Figure 
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5.4. In the GIF-oGM-CSF complex displayed in Figure 5.4A, the complex is 
stabilised by positive side-chains from GIF and negative side chains from oGM-CSF.  
A theoretical GIF-hGM-CSF complex is modelled in Figure 5.4B. The Leu23Arg 
mutation pushes positive residues into the vicinity of the Lys211 binding interface.  
The diminished binding ability of Lys211 is likely part of the reason GIF and hGM-
CSF have been reported not to form an interaction. 
 
Figure 5.4 Substitution of GM-CSF residues Leu23, Phe115 and Ile116. A) A section of the 
complex between GIF and oGM-CSF is pictured. GIF residues His232 and Lys211 are labelled. 
Nearby oGM-CSF residues are labelled; Arg23, Leu114, Phe115, Val116 and Ile117. B) The 
theoretical complex between GIF and hGM-CSF is modelled. GIF residues His232 and Lys211 are 
labelled. Nearby hGM-CSF residues are labelled; Arg23, Leu114, Leu115, Val116 and Ile117. GIF 
carbon molecules are coloured turquoise, while GM-CSF is coloured pink. All other atoms are as 
follows: nitrogen = marine blue; oxygen = red; sulfur = orange and hydrogen = white. Figure 
modelled on PyMOL (Schrodinger) using PDB file 5D28, submitted by Felix et al. (2016). 
GIF residue Trp43 forms a hydrogen bond with Leu23 and Asn27 of oGM-CSF. In 
hGM-CSF, Asn27 is conserved while a Leu23Arg mutation has occurred. This 
replaces the non-polar sidechain of leucine with a large polar and positively charged 
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side chain. This interaction is displayed in Figure 5.5. The Leu23Arg substitution 
results in a large positive sidechain clinging to the face of hGM-CSF. Electrostatic 
repulsion would almost certainly prevent the formation of a hydrogen bond between 
Tr43 and Asn27, which also reduces the likelihood of a close hydrogen bond forming 
between Trp43 and Leu23. 
 
Figure 5.5 Substitution of GM-CSF residue Leu23. A) The GIF-oGM-CSF complex is played. GIF 
residue Trp43 is labelled. oGM-CSF residues Asn27 and leu23 are labelled. B) A theoretical complex 
between GIF and hGM-CSF. Trp43 from GIF is labelled, as well as Asn27 and Arg23 from hGM-
CSF. The GIF carbon molecules are coloured turquoise, while GM-CSF is coloured pink. All other 
atoms are as follows: nitrogen = marine blue; oxygen = red; sulfur = orange and hydrogen = white. 
Figure modelled on PyMOL (Schrodinger) using PDB file 5D28, submitted by Felix et al. (2016). 
In the GIF-oGM-CSF complex, Asp17 forms hydrogen bonds with Tyr228 and 
Arg188 from GIF, while Lys20 forms a hydrogen bond with Gln41. Alanine-
substitution experiments have been reported to result in a 21.1-fold reduction in 
oGM-CSF-GIF affinity. Both Asp17 and Lys20 are substituted to Asn and Gln, 
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respectively. The original GIF-oGM-CSF complex and a theoretical hGM-CSF GIF 
interaction can be seen in Figure 5.6A and B. The change in structure is 
unfavourable, as the change from Asp to Asn loses a hydroxide group and introduces 
an amine group. The change from Lys to Gln similarly disrupts electrostatic 
attraction and would likely ameliorate binding.  
 
Figure 5.6 Substitution of lys20 and Asp17 causes steric hindrance. A) A section of the complex 
between GIF and oGM-CSF is pictured. GIF residues Tyr228, Arg188, Phe212, Pro191 and Phe 123 
are labelled. Asp17 and Lys20 from oGM-CSF is labelled. B) The theoretical complex between GIF 
and hGM-CSF is modelled. The same GIF residues are labelled. hGM-CSF residues Asn17 and are 
Gln20 are labelled. carbon molecules are coloured turquoise, while GM-CSF carbons are coloured 
pink. All other atoms are as follows: nitrogen = marine blue; oxygen = red; sulfur = orange and 
hydrogen = white. Figure modelled using PDB file 5D28, submitted by Felix et al. (2016). 
In addition to electrostatic interactions and hydrogen bonds, the GIF-oGM-CSF 
complex is also stabilised by van der Waals (VDW) contacts. While VDW contacts 
are comparatively weak, the cumulative attraction can be considerable. As the GIF 
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interface with oGM-CSF is largely positive, the substitution of three hGM-CSF 
residues to positive residues could disrupt electrostatic interactions by repelling 
positive GIF residues. 
5.1.3 Summary  
- Human GM-CSF retains high sequence identity with ovine and bovine 
homologs 
- Seven out of 23 substitutions between oGM-CSF and hGM-CSF are residues 
involved in GIF complex formation 
- Visualisation of a theoretical GIF-hGM-CSF complex demonstrates how 
certain substitutions make complex formation unfavourable 
- Felix et al. (2016) determined crucial residues for GIF-oGM-CSF complex 
formation. The residues on oGM-CSF bound by these GIF residues have 
undergone sterically unfavourable substitutions in several cases. 
5.2 Structural basis for GIF-IL-2 complex formation 
5.2.1 Overview 
GIF is known to bind oIL-2 but a high-resolution structure of a GIF-IL-2 has not yet 
been elucidated. A low-resolution EM image of this complex has been reported 
(Felix et al., 2016). It was decided to investigate the feasibility of this mechanism by 
observing other structures of IL-2 in quaternary complex and compare to possible 
interactions with the GIF protein.  
5.2.2 Sequence variation of IL-2 homologs 
Similar to the GM-CSF homologs described in 5.1.1, IL-2 homologs share 
considerable sequence homology.  
Human and ovine IL-2 share an identity of 63.7%. As the structure of the GIF-oIL-2 
complex is unknown, it is harder to draw conclusions on the effect of each 
substitution.  
Ovine and bovine IL-2 share high homology and an even higher similarity of 99%. 





Figure 5.7 Sequence identity of IL-2 homologs. Conserved residues displayed as white letters with 
red backgrounds. Where there is no consensus letters are black with no background colour. Where 
there is a majority consensus/similarity the position has a black outline, identical/similar residues are 
coloured red, while the dissimilar variant is coloured black. Secretion signal peptides have been 
removed from sequences. Alignment file rendered on ESPript 3.0. 
 
Figure 5.8 Sequence identity between ovine and human IL-2. Conserved residues displayed as 
white letters with red backgrounds. Consensus sequence is displayed below, a ‘.’ indicates no match, 





Figure 5.9 Consensus and sequence similarity between IL-2 variants. A) Consensus tree of IL-2 
variant amino acid sequence. B) Similarity table of IL-2 variant amino acids. Amino acid sequences 
aligned using Clustal Omega version 1.2.2. Consensus tree produced using UPGMA method. 
Displayed amino acid similarity % calculated by Blosum 45 with threshold 1. All % values rounded to 
two decimal places. 
 
5.2.3 Examining the putative GIF-IL-2 interface 
It was decided to observe the binding mechanism of IL-2. As a high-resolution image 
of the GIF-IL-2 structure has not been reported, it was decided to make predictions 
based on IL-2 complex formation. A low-resolution EM image of the IL-2-GIF 
complex exists. R188A reduced the affinity of complex formation of GIF and oGM-
CSF by ten-fold. 
IL-2 is primed for quaternary complex formation by initially binding IL-2Rα. In this 
conformation, IL-2Rα sits on top of IL-2, leaving amino acids forming helix D of IL-
2 exposed for binding the γC receptor (Figure 5.10). In the EM structure of the GIF-
oIL-2 complex by Felix et al. (2016), displayed in Figure 1.1., GIF interacts with the 
tip of Helix D and surrounding residues. 
The tip of helix D on IL-2 can be seen to interact with the γC receptor, stabilised by 




Figure 5.10 Model of primed IL-2 with IL-2Rα. IL-2 and IL-2Rα monomers are labelled and 
colour-coded. IL-2Rα is red, IL-2 is blue. IL-2 helices (A-D) are annotated. Model rendered in 





Figure 5.11 Model of primed IL-2 in complex with IL-2Rβ and γC. Image depicts the fully 
activated IL-2 quaternary complex of IL-2, IL-2Rα and γC on the extracellular membrane. Helices 
names are annotated. Figure modified from Wang et al. (2005), reproduced with permission from the 
American Association for the Advancement of Science (AAAS).  
 
The binding domain of the GIF protein has been reported to be predominantly 
positively charged. It was decided to examine the properties of hIL-2 at the tip of 
Helix D, which oIL-2 has been reported to bind. A model of primed hIL-2 is 
displayed in Figure 5.12. The base structure of the protein is displayed as a cartoon, 
while individual amino acid side chains in both Helix A and B are displayed as 
sticks. The amino acids on Helix D are largely negative, while the amino acids on 
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Helix A are largely negative. The positive negative residues on Helix D may 
facilitate the formation of a complex between GIF and IL-2. As no structures of 
primed oIL-2 have been reported, it was not possible to accurately model and make 
propositions of the structural basis of GIF-IL-2 complex formation. 
 
Figure 5.12 Examination of amino acids on Helix D of IL-2. Pictured here is a model of the tips of 
Helicies A and D of primed hIL-2. hIL-2 carbons are coloured pink, while IL-2Rα is coloured red. All 
other atoms are as follows: nitrogen = marine blue; oxygen = red; sulfur = orange and hydrogen = 
white. Model rendered in PyMOL using the crystal structure of IL-2-IL-2Rα deposited by Wang et al. 
2005. PDB code is 1Z92. 
 
5.2.4 Summary 
- hIL-2 and oIL-2 share lower sequence identity than GM-CSF homologs  
- The tip of Helix D of primed hIL-2 is comprised of predominantly negative 
residues, these may complement the positive residues on the GIF binding 
interface 
- GIF may bind oIL-2 on Helix D using a similar mechanism to the 






The aim of this research was to establish an expression and purification protocol for 
the GIF protein, as well as to measure the binding behaviour and examine the 
structural basis of complex formation. Chapter three described the results of 
subcloning, expression and transformation of DH5α cells with a DNA plasmid 
encoding the GIF construct. Chapter four described the glycosylation of GIF and its 
binding behaviour with human and bovine cytokines. Chapter five examined the 
structural basis of GIF binding mechanisms. This chapter discusses the results and 
implications for future research. Technical discussion about improving experimental 
systems are made throughout the chapter, while general future directions are 
discussed at the end. 
6.1  Expression and purification of the GIF protein 
6.1.1 Rationale for the use of HEK 293-6E cells for GIF expression 
GIF is a complex protein which is extensively glycosylated and contains three 
disulphide bonds. The presence of these post-translational modifications (PTMs) 
necessitated expression in eukaryotic cells, as bacterial expression systems lack the 
machinery for post-translational modification (PTMs) which can significantly reduce 
soluble protein yield (Tokmakov et al., 2012).  
HEK 293-6E cells were ultimately chosen for expression of GIF. GIF has previously 
been expressed in Chinese hamster ovary (CHO) cells and in higher quantities in 
HEK 293-T cells by other lab groups (Felix et al., 2016; McInnes et al., 2005). HEK 
293-T cells contain a portion of the SV40 large T antigen, allowing for expression of 
vectors containing the SV40 origin of replication. HEK 293-6E cells have a similar 
mechanism for increased expression of target protein; the Epstein Barr Virus (EBV) 
nuclear antigen 1 (EBNA1). EBV stores DNA extrasomaly, necessitating the use of 
additional machinery for transcription. EBNA1 is a DNA binding protein which 
recognises ‘OriP’ DNA sequences. ‘OriP’ is a highly effective promoter containing a 
region called family of repeats containing 21 copies of the EBNA1 binding site. 
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When EBNA1 recognises ‘oriP’, it increases transcription efficiency by localising 
oriP-containing DNA to the nucleus (Daikoku et al., 2004).  
DNA transfected into HEK 293-6E cells will also spend time in the cell cytosol 
which limits transcription, preventing optimal protein yield. Mimicking the 
expression mechanism of EBV for protein expression in HEK 293-6E cells has 
proven to be an effective mechanism for expression of target DNA, resulting in a 
three-fold increase in expression compared to non-oriP/EBNA1 expression systems 
(Tom et al., 2008).  
pTT5 is relatively small compared to other expression vectors, other options can 
range from 5-10 kbp (Pham et al., 2003; Yin et al., 2005). A smaller plasmid is 
desirable in transient transfection, as smaller plasmids are more stable and are 
trafficked to the nucleus more efficiently (Yin et al., 2005). The use of pTT5 for 
protein expression in HEK 293-6E cells is ideal as pTT5 contains ‘OriP’, which as 
previously mentioned is required for recognition by EBNA1. 
Transient transfection was mediated using polyethyleneimine (PEI), a cationic 
synthetic polymer. PEI binds tightly to DNA and induces folding into a globular 
shape, to the point that the DNA is encased by PEI and protected from cellular 
DNase enzymes (Godbey et al., 2000; Tiyaboonchai et al., 2003). 
6.1.2 Initial low-yield expression of the GIF protein 
The initial yield of GIF protein following IMAC purification was low and inadequate 
for the purposes of this project. The SDS-PAGE seen in Figure 3.9 reveals a faint 
band in fractions A4-A8. The band is near 43 kDa, which is the reported size of fully 
glycosylated GIF. The band also has blurred appearance, which is typical of 
glycoproteins like GIF due to heterogeneity in glycosylation state. Glycans are large 
molecular units compared to amino acids, so the addition or loss of a single glycan 
unit can cause an observable shift in location on an SDS-PAGE gel.  
The identity of the GIF protein was confirmed by LC-MS, seen in Figure 3.9. The 
band representing GIF had a 39% sequence overlap against the reference, an 
adequate sequence overlaps following trypsin digest. The missing sections of the GIF 
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protein likely did not have a trypsin cut site or were too small to detect in the 
Orbitrap XL™. 
The method of quantification may need to be improved in future. Glycoproteins are 
reported to undergo differential staining when dyed with Coomassie brilliant blue.  
6.1.3 Optimising basic expression parameters 
Optimisation of expression began by altering basic expression parameters; the 
amount of DNA used in transfections and the day of harvest post-transfection.  
It is important to ensure that an appropriate amount of plasmid DNA is delivered to 
the cells during transfection. Too little will lead to minimal expression as the DNA is 
acetylated and methylated, while too much DNA will lead to endoplasmic reticulum 
stress and a subsequent decrease in protein yield. The ratio of DNA to PEI has been 
reported to also be an important factor, but in the interests of time only the amount of 
DNA transfected was trialled. The standard amount of DNA used in the laboratory 
was 1 pg per HEK 293-6E cell. This was adjusted and trialled small-scale using 
0.0625, 0.125, 0.25, 1, 2, 3 and 4x the standard amount of DNA.  
The GIF bands in the western blot displayed in Figure 3.11 do not show considerable 
difference between cells treated with different amounts of DNA. This test is only 
indicative as it was not repeated. It was decided that the standard amount of DNA 
would be used for transfecting cells with GIF plasmid DNA.  
6.1.4 Trialling cell feeding 
Although we had optimised the basic parameters for GIF expression it was worth 
determining whether the addition of other agents to cell culture mix could result in 
statistically significant increases in GIF expression. Several agents were assessed 
based on practicality and measured effect on protein expression, and two were 
picked; peptone and valproic acid (VPA). 
VPA treatment has reportedly led to a 5.3-fold increase in protein yield in HEK 293-
6E cells, and peptone has been shown to increase yield by 2-fold (Backliwal et al., 
2008; Pham et al., 2003). Determining whether VPA, peptone or a combination of 
both increases the yield of GIF is worthwhile to obtain greater quantities of GIF (or 
other proteins) for downstream experiments.  
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After a transient transfection the DNA construct will be subject to degradation, as 
well as histone deacetylation and DNA methylation. This ultimately limits the 
amount of protein that can be produced during a transfection. In theory, a histone 
deacetylase inhibitor could prevent DNA degradation, thereby increasing protein 
expression (Durocher et al., 2002).  
Previous studies have reported a greater protein yield when cells are supplemented 
with valproic acid after transfection. This includes Felix et al. who solved the 
structure of GIF in complex with ovine GM-CSF (Felix et al., 2016). Valproic acid is 
a histone deacetylase inhibitor (iHDAC) with a well understood pharmacological 
profile.  
Another research group tested the effects of a variety of iHDACs including VPA on 
expression and concluded that valproic acid was the most effective (Backliwal et al., 
2008). A 5.3-fold increase expression yield in HEK 293-6E cells was reported when 
treated with 4 mM VPA 3 hours post-transfection. This study also investigated 
whether combinations of dimethyl transferase inhibitors (iDMTs) and iHDACs were 
effective in HEK 293-E cells, as a different study concluded that combination 
treatment was more effective in CHO cells (Choi et al., 2005). Backliwal et al. found 
that the reported effect was not the same in HEK 293-6E cells, both protein 
expression and cell viability were reduced compared to a no-treatment control.  
Pham et al. (2003) report that some peptones increase protein yield, however this can 
cause cellular aggregation. In 2005 they reported that peptone N1 from casein is the 
most efficient peptone for use, resulting in a two-fold increase in protein yield. They 
report optimal expression when cell mixture is augmented with 0.5% N1 peptone 24 
hours post-transfection. An increase of mRNA was also noticed, suggesting that 
peptone also upregulated gene transcription (Pham et al., 2005; Pham et al., 2003). 
These results concur with another report determining a 40-50% increase in protein 
yield at 72 hours post-transfection, with a 20-25% increase in mRNA levels 
(Carpentier et al., 2007). As the levels of mRNA were increased compared to the 
control, it is likely that the peptone had a direct effect on protein expression and did 
not somehow interact with downstream quantification. Although the exact 
mechanism is not thoroughly understood, the observed increase of transcription may 
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be due to the ability of the cell to sense metabolic state and adjust gene expression 
appropriately (Blagih et al., 2015; Proud, 2002). 
The expression trial undertaken in this project consisted of two important parts; the 
actual expression trial, and the method of analysis. Even if the expression trial was 
planned perfectly, insight into expressing GIF would not be possible if the method of 
analysis was flawed.  
The initial plan was to standardise the western-blot signal against His-tagged alanine 
racemase standards. While a suitable standard curve was produced, it was ultimately 
decided to pursue a different method of comparing expression of GIF between 
treatment groups. This decision was made for various reasons. A major problem with 
the western blot method was reproducibility. Multiple attempts were made to create a 
western blot with a suitable standard curve of alanine racemase, however only one 
was successful. As the SDS-PAGE and subsequent western blotting protocols are 
identical for quantifying alanine racemase and GIF, the same problems could 
continue when western blotting GIF. Due to the nature of using a system with; a 
primary antibody, a secondary antibody and a detection system, the relationship 
between signal strength and protein is not always linear (Charette et al., 2010). It 
would be harder to detect errors when quantifying GIF as the absolute amount of 
protein in each well is unknown. This could lead to erroneous results and inaccurate 
conclusions being drawn, which would affect the remainder of the project.  
The method for measuring expression by His-trap purification was devised as there 
were less steps involved, and the GIF protein produced in the trial could still be used 
for purification trials and assays.  
Supplementation of media with PBS control produced the highest peak, while 
supplementation of media with VPA resulted in a decreased peak compared to 
control. The control peak average was less than 0.5 mAu higher than peptone, while 
one peptone sample had the highest peak at 62 mAu. It was decided to continue to 
use a total concentration of 0.5% peptone (w/v) in subsequent transfections.  
While VPA has been reported to increase expression yield, it has also been reported 
to damage cells. This information alongside the expression trial in this project led to 
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the decision to not use VPA in protein expression. It was therefore decided to 
continue with peptone supplementation (0.5% w/v) 24 hours post-transfection.  
This experimental system could be optimised further by integrating the area of peaks, 
as peak height alone does not consider the quantity of protein across the 
chromatogram. Taking samples from each fraction corresponding to the 
chromatography peak and determining the % composition of GIF using SDS-PAGE 
would also increase accuracy. 
Another parameter to test would be the temperature used to incubate transfected 
cells. Reducing the incubation temperature to 33 °C has been reported to reduce 
HEK 293 cell growth and increase protein expression (Lin et al., 2015). It is 
important to note that the behaviour of expressed proteins was not altered, as α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors produced in the 
study retained full binding capability. 
Transient transfection has been adequate for the scope of this project; however, 
further analysis of the GIF protein may require upscaling. If this project were to be 
continued, it may be beneficial to switch to a stable cell expression system, where the 
GIF insert would be integrated into the HEK cell genome, which could potentially 
resulti in a higher and more consistent yield. The GIF protein could be edited into the 
cell genome using CRISPR/cas, which has been reported with a targeting efficiency 
of over 25% (Yang et al., 2019). 
6.1.5 Purification protocol for the GIF protein 
An aim was to establish a protocol for optimal expression and purification of GIF at 
high yield and purity in order to complete downstream experiments. 
GIF was initially purified using a crude 5 mL His-trap FFcolumn (General Electric). 
This is considered a rough initial purification, as the column binds many non-specific 
proteins, although having a higher sodium chloride or imidazole concentration can 
ameliorate this issue to some extent (Tsumoto et al., 2007). The column resin was 
charged with nickel as it has a higher affinity for His-tags, as the purpose of IMAC 
was to consolidate GIF into several fractions before further purification. GIF binding 
buffer also contained 10 mM imidazole, to further reduce non-specific binding. His-
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trap purification of GIF resulted in a bi-phasic peak. The first peak is higher and 
contains a variety of proteins, while the shoulder peak contains GIF, which is eluted 
primarily between 15-20% imidazole, before decreasing amounts of GIF can be seen 
in each fraction until the gradient reaches 100%. This elution profile could mean that 
the position of the tag in the protein is not fully accessible, or the glycosylation 
profile of GIF could be responsible.  
Although the GIF construct has a theoretical mass of 31.75 kDa, glycosylation is 
likely the reason for the mature protein being observed closer to 43 kDa. A band seen 
just above 40 kDa was suspected to be GIF (Figure 3.9A). The identity of putative 
GIF was confirmed by mass spectrometry (Figure 3.9B). Further purification steps 
were required as many other proteins could be seen with GIF.  
6.1.6 Anion exchange chromatography  
IEX was used as a second-step purification of GIF. The advantage of IEX was that it 
was able to separate GIF from all cationic proteins during the loading step, before 
eluting anionic proteins into different fractions based on pI. GIF has a theoretical pI 
of 6.75, however the addition of N-linked glycans would likely result in a 
considerably more negative charge. As the actual pI was unknown it was decided to 
use a MonoQ column, as the resin binds negative charges with high affinity. NaCl 
was removed from the buffer by dialysis to allow total GIF binding to the MonoQ 
resin. Removing NaCl from the buffer was problematic as protein precipitation was 
noticed after purification, an unnecessary loss of protein.  
For the purification protocol to be improved, a different second-step method of 
chromatography could be used. Hydrophobic interaction chromatography (HIC) may 
be suitable. HIC utilises a hydrophobic resin and an ammonium sulphate buffer to 
allow hydrophobic interactions between proteins and the resin. Bound proteins are 
eluted across a gradient of high to low ammonium sulfate. The least hydrophobic 
proteins are eluted first, while the most hydrophobic proteins are eluted last. While 




6.1.7 Separation of GIF and HSP70 
The presence of heat-shock protein 70 was unexpected and presented problems for 
downstream analysis. There may be some indirect evidence of GIF binding HSP70 in 
the literature, with Felix et al. describing the expression of GIF without either oIL-2 
or oGM-CSF as “prohibitory low” due to a propensity to aggregate (Felix et al., 
2016). The presence of HSP70 could be due to several reasons, as HSP70 is known 
to bind partially folded proteins to prevent degradation, as well as binding fully 
folded proteins to regulate activity. In this case GIF has been expressed in the 
absence of its binding partners, IL2 and GM-CSF, it is possible that it is unable to 
dimerise and form a stable conformation. In this case HSP70 could be preventing 
aggregation of the GIF monomer. 
Dialysis with HSP70 removal buffer appeared to be successful, as the proteins were 
visualised in different fractions after SEC in Figure 3.20.  
EDTA is a metal chelator, so it can bind the Mg2+ on HSP70. This, in theory, releases 
GIF from HSP70. The purpose of the activated charcoal is to bind ATP, preventing 
rebinding of HSP70 and GIF. Two main peaks were seen on the chromatogram and 
fractions corresponding to these peaks were analysed by SDS-PAGE. In fractions 
corresponding to the first peak, only the GIF protein was present. In later fractions, 
the HSP70 protein was seen, indicating that GIF was successfully separated from 
GIF-HSP70 complex.  
The dialysis of GIF with EDTA and activated charcoal did appear to remove HSP70, 
however there are other protocols which could also remove it. If purification were 
attempted again, HSP70 would be removed during the first step of purification using 
a modified IMAC protocol. Buffered HEK 293-6E supernatant would be loaded onto 
the column and washed, adenosine diphosphate (ADP) would then be run slowly 
through the column. The hypothesis is that HSP70 would instead bind to the ADP 
and would be removed from the column. This method would save time and remove 
the need for overnight dialysis, a step which is low-risk but lengthy and can still lead 
to precipitation.  
It was decided not to remove the His-tag from the GIF protein as the yield was low; 
carrying out cleavage followed by further chromatography would likely lead to 
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additional losses. The His-tag was attached to the N-terminus of GIF which was not 
in proximity to the cytokine binding sites, making interaction unlikely (Felix et al., 
2016). 
The purification protocol described results in pure GIF; however, the efficiency 
could be optimised. A significant amount of GIF is lost during IEX chromatography, 
as seen in Table 3.3, this is almost certainly due to the lack of sodium chloride in the 
buffer. A replacement for the IEX step could be hydrophobic interaction 
chromatography (HIC). HIC works on a similar principle to IEX, as it separates 
proteins based on hydrophobicity. This does not require the removal of salt from the 
buffer, which would bypass the issue of precipitation. There is still the risk of 
precipitation with high salt concentrations used in HIC, however this is another 
parameter which can be optimised.  
Another potential purification option could be to use Concanavalin A, a lectin unit 
derived from beans which binds glycoproteins with high affinity (Bhattacharyya et 
al., 1987; Lee et al., 2008). This method would be ideal as there is no need to reduce 
sodium chloride concentration, preventing GIF precipitation. Concanavalin A was 
not able to be used with the current phosphate buffer due to precipitation. The 
required binding and elution buffers for concanavalin A both required calcium 
chloride and manganese chloride. Both are cation chlorides and are prone to 
precipitating as the cation binds the hydroxyl-group of NaOH used for balancing pH 
in the phosphate buffer. In order to purify GIF using Concanavalin A, a tris-based 
buffer could be tested. 
6.2 Structure and binding behaviour of the GIF protein 
6.2.1 Glycosylation of the GIF protein 
Glycosylation is a PTM where a glycan is attached to an amino acid in a protein. 
Glycosylation of a protein is able to alter its properties for various purposes, 
including; folding, cell signaling and recognition, secretion from the cell and an 
extended half-life. The aforementioned properties make glycosylation an important 
consideration in the development of biotherapeutics. As glycosylation is 
heterogenous and can vary according to the expression system used, it was important 
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to analyse glycosylation of the GIF protein in our system and contrast it with other 
reports in the literature. 
The two main types of glycosylation are N-linked glycosylation and O-linked 
glycosylation. In N-linked glycosylation the glycan unit is attached to a nitrogen 
atom on an asparagine residue, where as in O-linked glycosylation the glycan is 
attached to an oxygen or hydroxyl group on a serine, threonine or tyrosine. Kinetic 
studies have revealed that de-glycosylation of GIF prevents binding with ovine 
cytokines entirely (McInnes et al., 2005). The glycosylation may be necessary for the 
supporting the structure of dimeric GIF. Although the glycosylation of GIF has 
previously been reported, it was important to ensure that the glycosylation found in 
the construct used this project displayed results that were consistent with prior 
studies. 
In Figure 4.2 four Asn residues were predicted to be glycosylated. To check for the 
presence of glycosylation in the GIF purified from our construct it was treated in 
vitro using PNGaseF, seen in Figure 4.4. Two clear and concise bands can be seen 
near 31 kDa. These are likely the GIF protein and PNGaseF. The GIF control 
appeared as a thick blurry band at 43 kDa, which was consistent with previous 
reports of GIF, while deglycosylated GIF was 31 kDa. It was confirmed that 
glycosylation was the cause of the blurry GIF band which had been observed 
previously, as deglycosylated GIF appeared as a sharp band.  
After confirming that GIF was subject to N-linked glycosylation, it was decided to 
observe the effects of glycosylation on protein secretion. Tunicamycin was used to 
prevent glycosylation of the GIF protein during expression. In Figure 4.5 the GIF 
protein appeared at 33 kDa when cells were treated with tunicamycin during 
expression. 33 kDa is approximately 25% less than the original observed size.  
In addition to this, in vitro de-glycosylation of GIF was found, as expected, to 
prevent its secretion from the cell. This was determined as western blots showed that 
deglycosylated GIF was only found in the cell pellet at 31 kDa, and not in the 
supernatant. The control glycosylated GIF appeared at 43 kDa in the cell supernatant. 
In the control pellet there was a thick blurry band just below the size of fully 
glycosylated GIF. This is likely to be a partially glycosylated form that has not been 
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secreted, indicating that GIF requires full glycosylation to be secreted from the cell. 
These results concur with similar studies from previous reports (McInnes et al., 
2005).  
It was concluded that the glycosylation profile of GIF was similar to other reports in 
the literature. Structural studies of GIF in complex with ovine GM-CSF determined 
that one side of GIF is heavily glycosylated, this is the side not involved in binding 
(Felix et al., 2016). Deglycosylated GIF has been reported not to bind either cytokine 
(McInnes et al., 2005), which may indicate that the glycans have an important role in 
maintaining GIF structure.  
The identity of each Asn-linked glycan was not determined in this project. This could 
be completed in future at the CPR in Otago using MS. Asn-linked glycans can be 
identified using isobaric tandem mass tags and the LTQ Orbitrap MS system (Ye et 
al., 2013). In this project it was decided not to check for O-linked glycosylation. 
While two residues were predicted to undergo O-linked glycosylation, it has been 
reported not to occur (Felix et al., 2016; McInnes et al., 2005). O-linked 
glycosylation could be checked for in future using commercially available O-linked 
deglycosylation kits. 
6.2.2 ELISA with bovine IL-2 
The results of the ELISA indicate a diminished ability of the GIF protein to bind 
bovine IL-2. Initial attempts at ELISA used varying concentrations of GIF and bIL-2 
to establish an appropriate range in which to elucidate an IC50. This was not achieved 
even with a substantial molarity ratio of GIF to bIL-2.  
It is possible that GIF binds bIL-2 with greater affinity than indicated in the ELISA. 
A hypothesis put forward by Felix et al. (2016) suggests that GIF binds only a small 
region of IL-2, the steric hindrance from this interaction would prevent oIL-2 from 
binding IL-Rα and not IL-2Rβ or γC. This means that using ELISA to determine 
binding affinity between GIF and IL-2 variants might not always be a reliable nor 
accurate option. It was not possible to examine where the detection antibody bound 
bIL-2, as the information is proprietary. 
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An alternative method of testing the binding affinity between GIF and hGM-CSF 
may be using surface plasmon resonance (SPR). SPR can be used to determine both 
affinity and kinetics for protein interactions using relatively small amounts of 
protein. It does not rely on antibodies or labelling so the problems with the bIL-2 
ELISA kit could be bypassed. 
6.2.3 ELISA with hGM-CSF and hIL-2  
Sandwich ELISAs of GIF and hIL-2 are displayed in Figure 4.7. There is no 
observed decrease in detected levels of hIL-2 with any concentration of GIF. This 
indicates that GIF did not bind hIL-2 in the sandwich ELISA. 
A sandwich ELISA with GIF and hGM-CSF is displayed in Figure 4.8. The level of 
hGM-CSF does not drop below the level used in each well. At some data points the 
level of detected hGM-CSF increased considerably. This was likely due to the fact 
that the TMB substrate turned blue within minutes. The reaction was stopped by 
pipetting 2 N sulfuric acid into each well from the top of each column of wells to the 
bottom using a multi-channel pipette. As datapoints 8 and 16 were in the lowest row 
of the plate, the TMB substrate had additional time to react and therefore have a 
greater absorbance at 450 nm. This issue could be solved by reducing the level of 
detection antibody or reducing the time of pre-binding to 15 minutes. This would 
slow the reaction of TMB consistently between wells and would increase accuracy of 
the assay system.  
The results from sandwich ELISAs with GIF and hGM-CSF and hIL-2 indicate that 
GIF binds neither. This was expected as GIF has been reported not to bind either 
when measured by several measurement techniques. 
6.2.4 Cell proliferation assay with TF-1 cells  
TF-1 cells are derived from a human erythroleukemia tumour and are dependent on 
IL-3 and/or GM-CSF for growth (Kitamura et al., 1989). 
TF-1 cells treated with GIF had a lower proliferation rate than the control. This result 
was unexpected as GIF has been reported not to bind hGM-CSF (Deane et al., 2000; 
Felix et al., 2016). hGM-CSF has a high structural homology with both oGM-CSF 
and bGM-CSF; however, there are currently no explanations why GIF binding with 
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hGM-CSF is totally ameliorated. Work in silico began to investigate the structural 
reasons why GIF can’t bind hGM-CSF; and if a very transitory interaction was 
possible, which would explain the results found here. 
Cells treated with hGM-CSF and GIF consistently had reduced cell metabolism 
compared to cells treated with hGM-CSF alone. It is possible that GIF and hGM-
CSF have a weak and transient interaction, which would explain why they did not 
appear to interact in more direct measurements of binding. 
It makes sense that GIF can bind both ovine and bovine cytokines due to the 
sequence homology and the retention of specific hot spots involved in binding. 
Interestingly, most of the amino acid substitutions between hGM-CSF and oGM-CSF 
are located on the interface between GIF and GM-CSF.  
Human IL-2 and GM-CSF still retain considerable homology, however, differ in 
sequence at important residues involves in binding. From the results of this project it 
was concluded that it is possible that GIF does bind human GM-CSF, however with 
low affinity resulting in a transitory interaction.  
The TF-1 cell proliferation was not able to be successfully repeated in this project. 
The assay was repeated in triplicate using a steady concentration of hGM-CSF, as 
this resulted in the greatest difference between GIF and control in Figure 4.10. The 
assay failed and no inference could be made from the data. This was likely due to 
human error.  
6.3 Examination of GIF binding profile 
The current project and the wider study of repurposing GIF as a novel protein 
therapy has vast and exciting scope for further research.  
Human GM-CSF and IL-2 share extensive sequence homology with bovine, ovine 
and murine variants. Despite the high homology, GIF has been reported to not bind 
either hGM-CSF or IL-2. Cell proliferation assay testing the proliferation of cells that 
were treated with GIF had a lower proliferation rate than control cells without GIF. 
There are no published reports in the literature that suggest a mechanism for this 




6.3.1 Structural basis of GIF binding GM-CSF 
The aim of in silico analysis of the GIF-oGM-CSF was to answer two main 
questions; 
• What is the structural cause of GIF not binding hGM-CSF? 
• Could GIF be engineered to bind hGM-CSF? 
Ala-substitution experiments to identify GIF residues crucial for formation of the 
GIF-oGM-CSF residues have been reported by Felix et al. A list of bonds at the 
interface between GIF and oGM-CSF were available in the supplementary material 
of Felix et al. (2016). The oGM-CSF residues that formed bonds with the GIF 
protein were noted. The PDB file 5D28 was modified on PyMOL (Schrödinger). 
oGM-CSF residues that formed bonds with GIF were mutated to the residues of 
hGM-CSF.  
At the time of writing, there has been one published report of the X-ray crystal 
structure of GIF in complex with oGM-CSF to a resolution of 2.7 Å (Felix et al., 
2016). No other structures have yet been reported. GIF and oGM-CSF bind through 
electrostatic interaction and specific hotspot binding. At the complex interface, GIF 
presents largely positively charged residues, while oGM-CSF residues are 
predominantly negatively charged. GIF also takes advantage of specific oGM-CSF 
residues used in binding the GM-CSF receptor. This includes using Lys211 to ‘cap’ 
the αD helix of oGM-CSF and is the same technique used by Arg302 of GMRα 
(Felix et al., 2016). Furthermore, GIF residues Gln108, Tyr110 and Arg45 interact 
with Asp112 of oGM-CSF, which is known to be essential for GMRα binding. 
The observed non-binding of GIF and hGM-CSF is likely due to a series of 
substitutions affecting residues spatially across the binding interface. Each individual 
mutation is unlikely to prevent binding independently, however the type of mutation 
and the location may prevent the formation of a GIF-hGM-CSF complex. These 
substitutions were described in 5.1.2. Residues in oGM-CSF that have been reported 
to be essential were found to be substituted in hGM-CSF.  
In this project, mutagenesis protein modelling involved mutating amino acids from 
oGM-CSF to hGM-CSF substitutions. Rotamers were selected based on the 
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likelihood of a rotamer occurring while GM-CSF was in complex with GIF. It is 
important to note that this method has drawbacks, as unbound hGM-CSF would 
likely not have those rotamers. Most rotamers selected resulted in amino acid side-
chains ‘hugging’ the face of the protein, due to unfavourable interactions with GIF. 
In unbound hGM-CSF, the sidechains would likely propel ‘outwards’, as there would 
be less unfavourable interactions from GIF. 
It is likely that the formation of a strong complex between GIF and hGM-CSF is 
prevented by a series of substitutions between oGM-CSF and hGM-CSF residues 
critical for complex formation. The TF-1 cell proliferation assay displayed in Figure 
4.10 indicated that a weak interaction may occur which has not been detected 
directly. In Felix et al. (2016) the authors note that the GIF-oGM-CSF has slow 
association kinetics. The series of hGM-CSF substitutions described in 5.1.2 would 
likely decrease the association rate significantly.  
The advantage of the TF-1 cell proliferation assay is that it does not measure affinity 
as a binary bound or unbound relationship. Complex formation can be detected by 
sequestering the TF-1 cell growth factor. While each GIF-hGM-CSF interaction may 
be transitory, the withheld hGM-CSF reduced proliferation of cells. 
To confirm this interaction, the assay should be repeated using a steady concentration 
of hGM-CSF to stimulate growth. Different concentrations of GIF should be used, 
this may allow the establishment of binding kinetics of GIF and hGM-CSF.  
6.3.2 Structural basis of GIF binding IL-2 
In Figure 1.1 the EM fit shows that oIL-2 is in a vertical position, making minimal 
contact with the surface of GIF (Felix et al., 2016). This is an interesting proposition 
as GIF binds oIL-2 with high affinity, with a KD of 0.47 nM. This level of affinity 
may require more residue interactions between GIF and oIL-2. 
Felix et al. (2016) proposed that the structure of GIF allows it to bind activated IL-2 
with higher specificity than IL-2 alone. To understand the significance of this 
hypothesis, it is crucial to understand the mechanism of endogenous IL-2 receptor 
activation and signal transduction.  
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The structures of human IL-2 in complex with IL-2Rα and in complex with the 
trimeric receptor have been elucidated using X-ray crystallography (Wang et al., 
2005). As previously mentioned, the binding of IL-2 to IL-2Rα induces a 
conformational change facilitating the interaction between IL-2 and IL-2Rβ and γC. 
In the orientation that oIL-2 appears to bind GIF in the 3D EM model, IL-2 would 
still be able to bind IL-2Rα but would be unlikely to concurrently bind IL-2Rβ or γC 
due to steric hindrance. If this binding mechanism is accurate it means that GIF binds 
activated IL-2, but prevents signal transduction by mitigating the formation of the 
quaternary receptor complex (Felix et al., 2016).   
When the IL-2-IL-2Rβ complex forms a complex with γC, there is very little surface 
area contact and the formation of only two hydrogen bonds (Stauber et al., 2006). As 
IL-2 binds to endogenous receptors in a stepwise series, GIF may bind activated IL-2 
to prevent signal transduction, contributing to the ability of orf virus to evade 
immune response. The 3D EM model suggests that GIF binds IL-2 in similar areas 
that IL-2 would normally bind the IL-2Rβ and γC receptors. One possible 
explanation is that GIF provides decoy residues to sequester IL-2 in a conformation 
like that of the endogenous receptor.  
It appears likely that GIF may have a higher affinity for IL-2 when in the IL-2-ILRα 
complex. To investigate this, IL-2 and IL-2Rα could be co-expressed with GIF 
before crystallisation trials to gain a high-resolution structure. The current binding 
pattern proposed shows minimal contacts between GIF and oIL-2, despite a high-






6.4 Future directions 
- Further optimise expression and purification as discussed previously in 6.1. 
- Co-express IL-2 and IL-2Rα and begin crystallisation trials with GIF. It 
appears likely that the GIF-IL-2-IL-2Rα structure would be more favourable  
- Repeat TF-1 cell proliferation assay to establish GIF-hGM-CSF binding 
behaviour 
- Semi-rational engineering of the GIF protein to produce mutants which may 
bind hGM-CSF. 
In the case that mutant GIF constructs bind hGM-CSF, patents should be obtained to 
protect intellectual property. This could be done in partnership with the Centre for 







This research has established a protocol for GIF expression and purification, verified 
glycosylation and binding behaviour as well as examine the structural basis of GIF 
interactions. 
A GIF construct was designed and produced for expression using transient 
transfection in HEK293-6E cells. One pg of DNA per cell was used in transfection. 
The expression mixture was supplemented to 0.5% (w/v) peptone and harvested 
three days post-transfection. A purification protocol for GIF was established, 
consisting of IMAC, IEX and SEC. The final SEC purification was completed using 
a special buffer to separate GIF from HSP70. 
Asn-linked glycans were removed from the GIF protein, reducing its observed 
molecular weight from 43 kDa to just over 31.75 kDa. Preventing glycosylation in 
vivo during expression using tunicamycin prevented GIF from being secreted from 
the cell.  
GIF bound bIL-2 in ‘sandwich’ ELISAs, but not hIL-2 or hGM-CSF. A cell 
proliferation assay with TF-1 cells revealed that cells treated with GIF had a lower 
proliferation rate than cells no treated with GIF, possibly indicating that GIF and 
hGM-CSF can form some sort of complex.  
The structural basis of GIF binding oGM-CSF was examined using PyMOL. 
Sequence alignments revealed that a number of crucial residues involved in forming 
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Appendix 2 BSA standard curve  
 
Appendix 3 – Full elution chromatogram from SEC purification of GIF in Figure 3.17 
 
Sandwich ELISA calibration curves 
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Appendix 4 Calibration curve for bIL-2 ELISA 
 
Appendix 5 Calibration curve for hGM-CSF ELISA 
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